<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Chronic kidney disease in children: Complications</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Chronic kidney disease in children: Complications</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Chronic kidney disease in children: Complications</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Authors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Bradley A Warady, MD</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Darcy K Weidemann, MD, MHS</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Tarak Srivastava, MD</a></dd><dt><span> </span>Section Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Tej K Mattoo, MD, DCH, FRCP</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Alison G Hoppin, MD</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Jul 11, 2023.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H1152798323"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>Chronic kidney disease (CKD) refers to a state of irreversible kidney damage and/or reduction of glomerular filtration rate (GFR) that is associated with progressive loss of kidney function over time. The loss of kidney function leads to a wide range of complications, which become more prevalent with progressive kidney function decline  (<a class="graphic graphic_table graphicRef89808" href="/d/graphic/89808.html" rel="external">table 1</a>).</p><p>Complications of pediatric CKD and their management are discussed here. The etiology, epidemiology, progression, clinical manifestations, and overview of management of CKD in children are discussed separately. (See  <a class="medical medical_review" href="/d/html/6115.html" rel="external">"Chronic kidney disease in children: Definition, epidemiology, etiology, and course"</a> and  <a class="medical medical_review" href="/d/html/6134.html" rel="external">"Chronic kidney disease in children: Clinical manifestations and evaluation"</a> and  <a class="medical medical_review" href="/d/html/6085.html" rel="external">"Chronic kidney disease in children: Overview of management"</a>.)</p><p class="headingAnchor" id="H1941571480"><span class="h1">DEFINITIONS</span><span class="headingEndMark"> — </span>CKD is defined as the presence of structural or functional kidney damage that persists over a minimum period of three months. Functional damage is characterized by sustained reduction of estimated glomerular filtration rate (eGFR), persistent elevation of urinary protein excretion, or both.</p><p>Based on this definition, clinical practice guidelines from the Kidney Disease: Improving Global Outcomes (KDIGO) in 2012 published criteria for diagnosis and staging of pediatric CKD [<a href="#rid1">1</a>]. The KDIGO staging classification is the standard used in clinical practice, research, and public health in the care of children with CKD greater than two years of age based on GFR and will be used throughout this topic  (<a class="graphic graphic_table graphicRef89808" href="/d/graphic/89808.html" rel="external">table 1</a>). This classification system defines pediatric CKD as follows:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Children ≥2 years</strong>:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>GFR &lt;60 mL/min per 1.73 m<sup>2</sup> for more than 3 months, <strong>or</strong></p><p></p><p class="bulletIndent2"><span class="glyph">•</span>GFR &gt;60 mL/min per 1.73 m<sup>2</sup> that is also accompanied by evidence of structural damage or other markers of functional kidney abnormalities including proteinuria, albuminuria, renal tubular disorders, or pathologic abnormalities detected by histology or inferred by imaging. This category also includes patients with solitary kidney or functioning kidney transplants.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Children &lt;2 years</strong> – Children under two years of age do not fit within the above classification system, because they physiologically have an inherently lower GFR even when corrected for body surface area. In these patients, abnormal kidney function based on serum creatinine can be compared with age-appropriate normative values to detect kidney impairment  (<a class="graphic graphic_table graphicRef116099" href="/d/graphic/116099.html" rel="external">table 2</a>). The KDIGO guideline suggests that a serum creatinine value more than one standard deviation above the mean should raise concern and prompt additional ongoing monitoring.</p><p></p><p>Additionally, the Chronic Kidney Disease in Children Under 25 GFR-estimating equation (U25 equation) has been validated in children with CKD as young as one year old [<a href="#rid2">2</a>] and <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fckid-gfrcalculator.shinyapps.io%2FeGFR%2F&amp;token=Jg5YMvd8AhVxbyA8UCl4y3D9Z72phVuxWARrH0Dw34UgMkoZA1IMqQgOLp2zpnRPQl6Q3HucSUALWeYgpAAzhw%3D%3D&amp;TOPIC_ID=128353" target="_blank">online calculators are available</a> for use. (See  <a class="medical medical_review" href="/d/html/6115.html" rel="external">"Chronic kidney disease in children: Definition, epidemiology, etiology, and course", section on 'Staging: Risk stratification'</a>.)</p><p class="headingAnchor" id="H3146374018"><span class="h1">OVERVIEW AND EPIDEMIOLOGY</span><span class="headingEndMark"> — </span>Moderate to severe loss of glomerular filtration rate (GFR; ie, GFR &lt;45 mL/min per 1.73 m<sup>2</sup> G3b to G5)  (<a class="graphic graphic_table graphicRef89808" href="/d/graphic/89808.html" rel="external">table 1</a>) may result in a number of complications due to kidney function impairment [<a href="#rid3">3</a>]. These complications include:</p><p class="bulletIndent1"><span class="glyph">●</span>Disorders of fluid and electrolytes</p><p class="bulletIndent1"><span class="glyph">●</span>CKD-mineral and bone disorder (CKD-MBD)</p><p class="bulletIndent1"><span class="glyph">●</span>Anemia</p><p class="bulletIndent1"><span class="glyph">●</span>Hypertension</p><p class="bulletIndent1"><span class="glyph">●</span>Dyslipidemia</p><p class="bulletIndent1"><span class="glyph">●</span>Malnutrition and poor growth</p><p class="bulletIndent1"><span class="glyph">●</span>Endocrine abnormalities</p><p class="bulletIndent1"><span class="glyph">●</span>Neurodevelopmental impairment</p><p class="bulletIndent1"><span class="glyph">●</span>Uremia</p><p></p><p>It is challenging to determine the prevalence of these complications as published data are observational in nature and vary regarding the severity of CKD and whether interventions have been instituted.</p><p class="bulletIndent1"><span class="glyph">●</span>In a single center retrospective study, the following prevalence rate of associated complications in 366 children with CKD were reported [<a href="#rid3">3</a>]. In this cohort, 57 percent of patients were in CKD stage G1, 29 percent in G2, 10 percent in G3a-b, and 4 percent were in stages G4 or G5.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Hypertension – 70 percent</p><p class="bulletIndent2"><span class="glyph">•</span>Anemia – 37 percent</p><p class="bulletIndent2"><span class="glyph">•</span>CKD-MBD – 17 percent</p><p class="bulletIndent2"><span class="glyph">•</span>Growth failure – 12 percent</p><p class="bulletIndent2"><span class="glyph">•</span>Electrolyte disorder or metabolic acidosis requiring intervention – 12 percent</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>In the multicenter prospective Chronic Kidney Disease in Children study, the following prevalence was reported based on data from 586 participants with moderate to severe CKD (median GFR = 43 mL/min/1.73 m<sup>2</sup>) [<a href="#rid4">4</a>].</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Anemia (hemoglobin [Hb] &lt;5<sup>th</sup> percentile or the use of erythropoietin) – 38 percent</p><p class="bulletIndent2"><span class="glyph">•</span>Growth failure (height &lt;3<sup>rd</sup> percentile) – 16 percent</p><p class="bulletIndent2"><span class="glyph">•</span>Uncontrolled systolic hypertension – 14 percent</p><p class="bulletIndent2"><span class="glyph">•</span>Uncontrolled diastolic hypertension – 13 percent</p><p></p><p class="headingAnchor" id="H2537233052"><span class="h1">FLUID AND ELECTROLYTE ABNORMALITIES</span></p><p class="headingAnchor" id="H216789000"><span class="h2">Sodium and water homeostasis</span><span class="headingEndMark"> — </span>Kidneys normally can adapt to a wide range of sodium and water intake. Sodium and intravascular volume balance are usually maintained via homeostatic mechanisms until the glomerular filtration rate (GFR) falls below 15 mL/min per 1.73 m<sup>2</sup>; however, some children with milder CKD may not adequately respond to acute intravascular volume depletion.</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Salt wasting and poor urinary concentration</strong> – Salt-wasting and the inability to appropriately concentrate urine are often observed in children with obstructive uropathy and/or dysplastic kidneys. These children are at risk for clinically significant hypovolemia due to their inability to respond appropriately to acute intravascular volume depletion. Despite fluid losses that occur during episodes of vomiting and/or diarrhea, these patients may continue to have substantial and falsely reassuring urine output and/or isosthenuria noted on urine-specific gravity (SG; ie, urine SG that reflects SG of protein free plasma, usually 1.010 to 1.015). This increases the risk of hypovolemia, with a potential decrease in perfusion to the kidneys and prerenal acute kidney injury. Small children and infants are especially vulnerable as they are unable to independently access or indicate the need for fluids and are totally dependent on caretakers for fluid replacement. The perpetual need for access to free water should be emphasized to the caretakers, especially when the child has an intercurrent illness that increases volume losses (eg, vomiting or diarrhea) or decreased fluid intake. Salt supplementation is also frequently required in infants and younger children, who may require an additional 1 to 5 mEq/kg of sodium supplementation daily [<a href="#rid5">5,6</a>]. Hyponatremia is frequently observed during periods of salt depletion but also may be noted in the setting of excess free water administration. (See  <a class="medical medical_review" href="/d/html/6085.html" rel="external">"Chronic kidney disease in children: Overview of management", section on 'Avoid subsequent kidney injury'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Salt and fluid overload</strong> – As the kidney function becomes severely compromised (GFR &lt;15 mL/min per 1.73 m<sup>2</sup>, stage G5), sodium and water retention may result in chronic intravascular volume overload. In general, a combination of dietary sodium restriction and diuretic therapy is used to prevent fluid overload:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Sodium</strong> <strong>restriction</strong> – We recommend sodium intake of less than 1500 to 2400 mg/day for children who require sodium restriction, consistent with guidelines from the Kidney Disease Outcomes Quality Initiative [<a href="#rid5">5</a>].</p><p></p><p class="bulletIndent2">This sodium restriction is often a difficult task given the sodium content of the favorite foods of children. Although the recommended daily sodium intake in healthy children is only 1.2 g/day for four- to eight-year-old children and 1.5 g/day for older children, this is substantially lower than the average intake in a healthy child in the United States [<a href="#rid7">7,8</a>].</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Diuretics</strong> – Diuretic therapy includes either loop diuretics such as <a class="drug drug_pediatric" data-topicid="13329" href="/d/drug information/13329.html" rel="external">furosemide</a> given at a dose of 0.5 to 2 mg/kg per day or thiazide diuretics such as <a class="drug drug_pediatric" data-topicid="13357" href="/d/drug information/13357.html" rel="external">hydrochlorothiazide</a> at 1 to 3 mg/kg per day. At our center, we typically use a thiazide diuretic in the early stages of CKD and a loop diuretic in the more advanced stages of disease when thiazide therapy may be less effective. Both classes of diuretics become less effective with decreasing GFR and may require higher mg/kg dosing to maintain desired effects on electrolyte stability and/or fluid balance.</p><p></p><p class="headingAnchor" id="H3184766579"><span class="h2">Hyperkalemia</span><span class="headingEndMark"> — </span>Hyperkalemia develops primarily because of inadequate potassium excretion due to a reduced GFR. Other factors that can contribute to elevated potassium levels include a high dietary potassium intake; increased tissue breakdown (rhabdomyolysis); hemolysis; metabolic acidosis; hypoaldosteronism (due in some cases to administration of an angiotensin-converting enzyme [ACE] inhibitor or an angiotensin II receptor blocker [ARB]); medication side effect (beta blockers, potassium-sparing diuretics, nonsteroidal antiinflammatory drugs); or impaired cellular uptake of potassium. Elevated serum potassium may also be due to voltage-dependent distal renal tubular acidosis, as may occur in children with obstructive uropathy [<a href="#rid9">9</a>]. (See  <a class="medical medical_review" href="/d/html/97159.html" rel="external">"Hypokalemia in children", section on 'Increased urinary losses'</a> and  <a class="medical medical_review" href="/d/html/14274.html" rel="external">"Causes, clinical manifestations, diagnosis, and evaluation of hyperkalemia in children", section on 'Abnormalities in renal excretion'</a>.)</p><p>Management to prevent hyperkalemia in children with CKD consists of the following and is consistent with the practice recommendations from the Pediatric Renal Nutrition Taskforce [<a href="#rid10">10</a>]. Specific interventions are presented separately in greater detail. (See  <a class="medical medical_review" href="/d/html/85908.html" rel="external">"Management of hyperkalemia in children"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Low-potassium diet</strong> – For infants taking a formula or children taking nutritional supplements, select a product that is low in potassium. Breast milk has low potassium content and should generally be encouraged for infants with CKD [<a href="#rid11">11</a>]. For formula-fed infants, formulas that are extremely low in potassium are commercially available (ie, Renastart or Renastep for older children) [<a href="#rid12">12</a>]. Since they are extremely low in other electrolytes except sodium, they are often combined with other nutritional formulas in children who require a potassium-restricted diet. The use of these formulas requires close medical supervision, ideally by a multidisciplinary team including a pediatric renal dietician.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Potassium binders</strong>:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Cation-exchange resins (eg, <a class="drug drug_pediatric" data-topicid="12799" href="/d/drug information/12799.html" rel="external">sodium polystyrene sulfonate</a> [SPS] or <a class="drug drug_pediatric" data-topicid="135029" href="/d/drug information/135029.html" rel="external">calcium polystyrene sulfonate</a>), are used to decrease the absorption of dietary potassium in children. Their use in children should be directed by a clinician with expertise in managing pediatric hyperkalemia. In the United States, calcium polystyrene sulfonate is not available. As a result, our center uses SPS in the following manner:</p><p></p><p class="bulletIndent3"><span class="glyph">-</span>For formula-fed infants, the formula can be mixed with SPS and decanted to decrease the potassium content of the formula prior to feeding [<a href="#rid13">13</a>]. Direct oral administration of cation-exchange resins has been associated with intestinal necrosis, and its use is contraindicated in neonates, especially premature infants. Use of SPS results in a decrease in calcium, magnesium, and copper and an increase in the iron, sodium, and aluminum content of the nutritional formula [<a href="#rid14">14</a>]. Due to the increased availability of multiple low-potassium nutritional products, in our experience, SPS-decanting is used primarily for infants who require a hydrolyzed or non-cow's protein-based formula.</p><p></p><p class="bulletIndent3"><span class="glyph">-</span>For older children, SPS is available as an oral suspension or rectal enema. When administered into the intestinal tract, approximately 1 mEq of potassium is exchanged per g of SPS, which also delivers 4.1 mEq of sodium per g of drug to the patient. Long-term use of SPS is limited due to poor patient tolerability, as a result of both the poor palatability and associated diarrhea.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><a class="drug drug_pediatric" data-topicid="143556" href="/d/drug information/143556.html" rel="external">Patiromer</a>, a potassium-binding polymer, has been studied in adults with CKD stage G3 or greater with hyperkalemia, but similar pediatric data are not available. In adults, patiromer decreased serum potassium level after four weeks of treatment compared with placebo and remained efficacious throughout the study period of 52 weeks with lower potassium levels and a reduction in recurrent episodes of hyperkalemia. Clinical trials are underway in children to determine if patiromer has similar beneficial effects without serious adverse effects. (See  <a class="medical medical_review" href="/d/html/2332.html" rel="external">"Treatment and prevention of hyperkalemia in adults", section on 'Patiromer'</a>.) [<a href="#rid13">13,14</a>]</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Correction of metabolic acidosis</strong> – Oral <a class="drug drug_pediatric" data-topicid="12795" href="/d/drug information/12795.html" rel="external">sodium bicarbonate</a> therapy can transiently improve hyperkalemia by inducing transcellular movement of potassium intracellularly. However, this is only a temporizing measure as it does not affect the overall body potassium load. (See <a class="local">'Metabolic acidosis'</a> below and  <a class="medical medical_review" href="/d/html/85908.html" rel="external">"Management of hyperkalemia in children", section on 'Sodium bicarbonate'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Correction of salt depletion</strong> – In children with obstructive uropathy or renal dysplasia, salt or volume depletion can result in hyperkalemia due to impaired distal sodium-potassium exchange in the distal tubule and cortical collecting ducts. This is best addressed with sodium supplementation and adequate fluid repletion. (See <a class="local">'Sodium and water homeostasis'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Diuretics</strong> – Administration of a thiazide or loop diuretic to increase urinary potassium loss. Thiazide diuretics may be most useful in the setting of mild hyperkalemia and/or in the setting of mildly impaired GFR. Loop diuretics, which have more potent diuretic and kaliuretic effects, may be most useful in CKD patients who experience significant concomitant extracellular volume expansion or who have more advanced CKD.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Kidney replacement therapy</strong> – Kidney replacement therapy may be necessary if conservative management fails to control severe symptomatic hyperkalemia, which may be associated with potentially life-threatening arrhythmias. (See  <a class="medical medical_review" href="/d/html/85908.html" rel="external">"Management of hyperkalemia in children", section on 'Dialysis'</a>.)</p><p></p><p class="headingAnchor" id="H92221770"><span class="h2">Hypokalemia</span><span class="headingEndMark"> — </span>Hypokalemia is less frequently observed in children with CKD but may occur in the following scenarios:</p><p class="bulletIndent1"><span class="glyph">●</span>Children with polyuria (eg, those with congenital anomalies of the kidney and urinary tract [CAKUT]) with chronic intravascular volume depletion, which may cause increased renin and aldosterone activity, which enhances urinary potassium losses and leads to hypokalemia.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Children with genetic tubular abnormalities resulting in increased urinary potassium loss, such as type II (proximal) renal tubular acidosis and Bartter syndrome.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Aggressive diuretic therapy (eg, for fluid retention or edema).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Severe acute malnutrition.</p><p></p><p>(See  <a class="medical medical_review" href="/d/html/97159.html" rel="external">"Hypokalemia in children"</a> and  <a class="medical medical_review" href="/d/html/6121.html" rel="external">"Etiology and clinical manifestations of renal tubular acidosis in infants and children"</a> and  <a class="medical medical_review" href="/d/html/2344.html" rel="external">"Inherited hypokalemic salt-losing tubulopathies: Pathophysiology and overview of clinical manifestations"</a>.)</p><p class="headingAnchor" id="H3318595016"><span class="h2">Metabolic acidosis</span><span class="headingEndMark"> — </span>The cause of metabolic acidosis with advanced kidney disease is related to the fall in total ammonium excretion that occurs when the GFR decreases to below 40 to 50 mL/min per 1.73 m<sup>2</sup> (stage G3). It is associated with an increased anion gap, which helps differentiate it from normal anion-gap metabolic acidosis that may occur in some patients with early CKD due to conditions of obstructive uropathy. In addition, there is a reduction in both titratable acid excretion (primarily as phosphate) and bicarbonate reabsorption. As the patient approaches CKD stage G5 (end-stage kidney disease), the serum bicarbonate concentration tends to stabilize between 12 and 20 mEq/L. A level below 10 mEq/L is unusual as buffering of the retained hydrogen ions by various body buffers prevents a progressive fall in the bicarbonate concentration. Acidosis is associated with growth impairment because the body utilizes bone buffering to bind some of the excess hydrogen ions. (See  <a class="medical medical_review" href="/d/html/14555.html" rel="external">"Growth failure in children with chronic kidney disease: Risk factors, evaluation, and diagnosis", section on 'Metabolic acidosis'</a>.)</p><p>We suggest providing enteral <a class="drug drug_pediatric" data-topicid="12795" href="/d/drug information/12795.html" rel="external">sodium bicarbonate</a> therapy in patients with metabolic acidosis to maintain the serum bicarbonate level at or above 22 mEq/L consistent with the Kidney Disease Outcomes Quality Initiative and Kidney Disease: Improving Global Outcomes (KDIGO) guidelines [<a href="#rid1">1,15</a>]. Sodium bicarbonate therapy is started at 1 to 2 mEq/kg per day in two to three divided doses, and the dose is titrated to reach the clinical target. Citrate preparations should generally be avoided in children with CKD as these preparations enhance aluminum absorption from the intestine and increase the risk of aluminum toxicity. (See  <a class="medical medical_review" href="/d/html/6100.html" rel="external">"Approach to the child with metabolic acidosis", section on 'Chronic metabolic acidosis'</a> and  <a class="medical medical_review" href="/d/html/1839.html" rel="external">"Aluminum toxicity in chronic kidney disease"</a>.)</p><p class="headingAnchor" id="H324172998"><span class="h1">CHRONIC KIDNEY DISEASE-MINERAL AND BONE DISORDER</span><span class="headingEndMark"> — </span>CKD-mineral and bone disorder (CKD-MBD) presents as a clinical spectrum, encompassing abnormalities in mineral metabolism, bone structure, and extraskeletal calcifications that are found with progressive CKD. CKD-MBD, when untreated, can first be detected in children with glomerular filtration rate (GFR) stage G2, who are typically asymptomatic but have abnormal laboratory findings (eg, decreased serum calcidiol and/or calcitriol levels and elevated serum parathyroid hormone and fibroblast growth factor 23 levels  (<a class="graphic graphic_figure graphicRef107125" href="/d/graphic/107125.html" rel="external">figure 1</a>)) [<a href="#rid16">16-18</a>]. Patients with more advanced CKD, if untreated, may have bone pain, difficulty in walking, skeletal deformities including rickets, growth impairment, avascular necrosis, vascular calcifications, and an increased risk of fractures [<a href="#rid19">19-23</a>]. (See  <a class="medical medical_review" href="/d/html/6134.html" rel="external">"Chronic kidney disease in children: Clinical manifestations and evaluation", section on 'Physical examination'</a>.)</p><p>CKD-MBD in children, including its management, is discussed in greater detail separately. (See  <a class="medical medical_review" href="/d/html/6092.html" rel="external">"Pediatric chronic kidney disease-mineral and bone disorder (CKD-MBD)"</a>.)</p><p class="headingAnchor" id="H1686093607"><span class="h1">ANEMIA</span><span class="headingEndMark"> — </span>Anemia due to reduced kidney erythropoietin production generally develops when the glomerular filtration rate (GFR) is below 40 mL/min per 1.73 m² [<a href="#rid24">24</a>]. At the onset of dialysis, the presence of anemia in children is very common and has been associated with excessive morbidity and an increased mortality risk [<a href="#rid25">25</a>]. If left untreated, the anemia of CKD is associated with fatigue, weakness, decreased executive function, increased somnolence, poor exercise tolerance, and growth impairment [<a href="#rid19">19,26-31</a>].</p><p>Because anemia occurs in all children with severe CKD (ie, stages G4 and G5) if untreated, guidelines have been developed for the early identification, evaluation, and treatment of anemia in children at all stages of CKD [<a href="#rid1">1,32</a>]. The recommendations for the management of anemia presented here are based on these sets of guidelines  (<a class="graphic graphic_algorithm graphicRef130059" href="/d/graphic/130059.html" rel="external">algorithm 1</a>).</p><p class="headingAnchor" id="H274531836"><span class="h2">Screening and evaluation of anemia</span><span class="headingEndMark"> — </span>Annual testing of hemoglobin (Hb) should be performed in children with CKD, regardless of stage or cause. A diagnosis of anemia is made when the observed Hb result is below the 2.5<sup>th</sup> percentile of normal, adjusted for age and sex  (<a class="graphic graphic_table graphicRef57465" href="/d/graphic/57465.html" rel="external">table 3</a>). (See  <a class="medical medical_review" href="/d/html/5927.html" rel="external">"Approach to the child with anemia", section on 'Definition of anemia'</a>.)</p><p>In any child with CKD and anemia, we perform the following evaluation, which is focused on identifying other potentially treatable causes of anemia (eg, iron deficiency)  (<a class="graphic graphic_algorithm graphicRef130059" href="/d/graphic/130059.html" rel="external">algorithm 1</a>) [<a href="#rid33">33</a>]. The anemia of CKD is principally normocytic and normochromic. The finding of microcytosis may reflect iron deficiency or aluminum excess, and macrocytosis may be associated with vitamin B12 or folate deficiency.</p><p class="bulletIndent1"><span class="glyph">●</span>Red blood cell indices</p><p class="bulletIndent1"><span class="glyph">●</span>Reticulocyte count</p><p class="bulletIndent1"><span class="glyph">●</span>Iron parameters (serum iron, total iron-binding capacity, percent transferrin saturation [TSAT], serum ferritin)</p><p class="bulletIndent1"><span class="glyph">●</span>Test for occult blood in stool</p><p></p><p>Interpretation of the results of these tests is discussed separately. (See  <a class="medical medical_review" href="/d/html/5927.html" rel="external">"Approach to the child with anemia", section on 'Diagnostic approach'</a>.) Evaluation for aluminum toxicity in CKD is discussed separately. (See  <a class="medical medical_review" href="/d/html/1839.html" rel="external">"Aluminum toxicity in chronic kidney disease"</a>.)</p><p class="headingAnchor" id="H340596099"><span class="h2">Treatment of anemia</span><span class="headingEndMark"> — </span>After eliminating other causes of anemia, treatment of anemia due to CKD includes iron supplementation (when indicated) and use of erythropoiesis-stimulating agents (ESA).</p><p class="headingAnchor" id="H2668583342"><span class="h3">Target hemoglobin</span><span class="headingEndMark"> — </span>We suggest a target Hb between 11 and 12 g/dL be maintained, which is consistent with published guidelines that are based on consensus expert opinion [<a href="#rid32">32,34,35</a>].</p><p>This target is supported by the following data:</p><p class="bulletIndent1"><span class="glyph">●</span>Hb levels below 10 and 11 g/dL are associated with increased mortality and morbidity in infants and children with CKD [<a href="#rid32">32,36</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Hb levels above 13 g/dL in adults are associated with an increased risk of cardiovascular-related events. As a result, there is a general consensus among experts in the field that adult targeted Hb levels should not exceed 13 g/dL in patients treated with an ESA (see  <a class="medical medical_review" href="/d/html/1952.html" rel="external">"Treatment of anemia in nondialysis chronic kidney disease", section on 'Target hemoglobin value'</a>). Limited retrospective data found that an Hb value &gt;12 g/dL was not associated with increased cardiovascular morbidity or mortality in pediatric hemodialysis patients [<a href="#rid37">37</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Hb Z-scores of less than -1.0 were independently associated with growth impairment at the subsequent study visit, and one-half of these participants corresponded to Hb values higher than the threshold guidelines used as anemia cutoffs in the Kidney Disease: Improving Global Outcomes (KDIGO) clinical practice guidelines for anemia in CKD [<a href="#rid31">31</a>]. (See  <a class="medical medical_review" href="/d/html/1926.html" rel="external">"Treatment of anemia in patients on dialysis"</a>.)</p><p></p><p class="headingAnchor" id="H2361156613"><span class="h3">Iron</span><span class="headingEndMark"> — </span>Iron therapy (elemental iron 2 to 6 mg/kg per day in two to three divided doses) should be initiated if iron deficiency is detected (microcytic anemia and low serum ferritin level). In our practice, which is consistent with published guidelines, iron supplementation is targeted to maintain a TSAT ≥20 percent and a serum ferritin ≥100 ng/dL in children with CKD [<a href="#rid33">33</a>]. We treat children with CKD who are not receiving hemodialysis with oral iron therapy. Intravenous iron therapy is reserved for children receiving hemodialysis or if the child not on dialysis is intolerant of oral iron or target Hb levels are not achieved with oral therapy.</p><p>Iron therapy should be given to all patients receiving therapy with an ESA to prevent the development of iron deficiency. Once the iron status is normal, iron parameters should be monitored at least every three months or monthly following the initiation of and/or increase in ESA dosing. (See  <a class="medical medical_review" href="/d/html/1951.html" rel="external">"Diagnosis of iron deficiency in chronic kidney disease"</a>.)</p><p class="headingAnchor" id="H609096979"><span class="h3">Erythropoiesis-stimulating agents</span><span class="headingEndMark"> — </span>Although primarily used in patients with end-stage kidney disease, ESAs (eg, recombinant human erythropoietin [rHuEPO], <a class="drug drug_pediatric" data-topicid="13206" href="/d/drug information/13206.html" rel="external">darbepoetin alfa</a>, or continuous erythropoietin receptor activator [CERA], <a class="drug drug_pediatric" data-topicid="121840" href="/d/drug information/121840.html" rel="external">methoxy polyethylene glycol-epoetin beta</a>) are also used to correct the anemia in some children at earlier CKD stages [<a href="#rid38">38,39</a>].</p><p>Increasing the Hb into an acceptable range in pediatric patients with anemia may ameliorate anemia-induced symptoms (eg, fatigue and exercise intolerance), result in cardiovascular improvement, and possibly delay progression of CKD and decrease mortality [<a href="#rid40">40</a>]. We suggest initiating ESAs when the Hb level is &lt;10 g/dL, provided that iron stores are replete with a TSAT &gt;25 percent and serum ferritin &gt;200 ng/mL. Iron supplementation is initially provided until iron stores are complete repleted to this level prior to ESA administration. (See  <a class="medical medical_review" href="/d/html/1952.html" rel="external">"Treatment of anemia in nondialysis chronic kidney disease"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Formulations and dosing</strong> – Initial dosing varies based on the choice of ESA, age of the patient, and severity of CKD. In our practice, the preferred ESAs are rHuEPO and <a class="drug drug_pediatric" data-topicid="13206" href="/d/drug information/13206.html" rel="external">darbepoetin alfa</a>. CERA is a longer-acting ESA with the potential benefit of improved adherence with less frequent dosing and reduced pain associated with the subcutaneous injection compared with darbepoetin.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>rHuEPO (<a class="drug drug_pediatric" data-topicid="13273" href="/d/drug information/13273.html" rel="external">epoetin alfa</a>) is administered:</p><p></p><p class="bulletIndent3"><span class="glyph">-</span>In children not receiving dialysis and those receiving peritoneal dialysis, by subcutaneous administration with rotation of the site of injection.</p><p></p><p class="bulletIndent3"><span class="glyph">-</span>In patients who receive hemodialysis, intravenously through their vascular access.</p><p></p><p class="bulletIndent3"><span class="glyph">-</span>The range of dosing is based on age and severity of CKD. For example, initial dosing for children ≥5 years of age not receiving dialysis is 80 to 120 units/kg per week, administered in two to three divided doses. Children younger than five years of age or children receiving dialysis typically require higher doses (as much as 300 units/kg per week).</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><a class="drug drug_pediatric" data-topicid="13206" href="/d/drug information/13206.html" rel="external">Darbepoetin alfa</a> is a long-acting erythropoietic agent and may be a preferred ESA for adolescents to improve compliance. Its threefold longer half-life and greater biologic activity compared with epoetin-alfa or epoetin-beta allows for less frequent dosing to effectively maintain a target Hb. Based on limited pediatric data, darbepoetin alfa can be given at a dose of 0.25 to 0.75 mcg/kg no more frequently than once weekly [<a href="#rid41">41-43</a>]. In a randomized controlled trial, darbepoetin alfa was shown to be effective and safe in 116 children with CKD-related anemia when administered either weekly or every two weeks to achieve Hb targets of 10 to 12 g/dL [<a href="#rid38">38</a>]. Similar to rHuEPO, darbepoetin is administered subcutaneously for patients not receiving dialysis or those on peritoneal dialysis, while intravenous administration is used for children on hemodialysis through their vascular access.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>CERA (<a class="drug drug_pediatric" data-topicid="121840" href="/d/drug information/121840.html" rel="external">methoxy polyethylene glycol-epoetin beta</a>), an ESA with a longer half-life compared with other ESAs, allows for once-monthly dosing. In the open-label multicenter DOLPHIN study of 64 children between 6 and 17 years of age undergoing hemodialysis, intravenous CERA was able to maintain stable Hb levels when patients were switched to CERA from either rHuEPO or <a class="drug drug_pediatric" data-topicid="13206" href="/d/drug information/13206.html" rel="external">darbepoetin alfa</a> using a conversion factor of 4 mcg every four weeks for each weekly dose of 125 international units <a class="drug drug_pediatric" data-topicid="13273" href="/d/drug information/13273.html" rel="external">epoetin alfa</a>/beta or 0.55 mcg darbepoetin [<a href="#rid44">44</a>]. Adverse side effects were similar to those reported in studies of CERA in adults and include hypertension and vascular access thrombosis, which are also observed with other ESAs. Intravenously administered CERA may be considered for use in children on hemodialysis. The SKIPPER multicenter randomized clinical trial determined that subcutaneous CERA was safe and efficacious for pediatric patients with dialysis-dependent and nondialysis-dependent CKD [<a href="#rid39">39</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Monitoring response</strong> – The response to ESA is monitored by measurement of the Hb every one to two weeks following the initiation of treatment or following a dose change regardless of which formulation is chosen. The expected increase in Hb after the initiation of rHuEPO therapy or after a dose change is between 1 to 2 g/dL over a two- to four-week period. Once a stable target Hb and ESA dose have been achieved, Hb measurement may be performed every four weeks.</p><p></p><p class="bulletIndent1">The most common cause of an incomplete response to an ESA is iron deficiency. However, other conditions in the iron replete patient may cause an inadequate response to an ESA as well and include:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Infection or inflammation (see  <a class="medical medical_review" href="/d/html/1939.html" rel="external">"Inflammation in patients with kidney function impairment"</a>)</p><p class="bulletIndent2"><span class="glyph">•</span>Chronic blood loss (see  <a class="medical medical_review" href="/d/html/5927.html" rel="external">"Approach to the child with anemia"</a>)</p><p class="bulletIndent2"><span class="glyph">•</span>CKD-mineral and bone disorder (CKD-MBD) [<a href="#rid45">45</a>] (see  <a class="medical medical_review" href="/d/html/1969.html" rel="external">"Overview of chronic kidney disease-mineral and bone disorder (CKD-MBD)"</a>)</p><p class="bulletIndent2"><span class="glyph">•</span>Aluminum toxicity (see  <a class="medical medical_review" href="/d/html/1839.html" rel="external">"Aluminum toxicity in chronic kidney disease"</a>)</p><p class="bulletIndent2"><span class="glyph">•</span>Folate or vitamin B12 deficiency (see  <a class="medical medical_review" href="/d/html/7154.html" rel="external">"Treatment of vitamin B12 and folate deficiencies"</a>)</p><p class="bulletIndent2"><span class="glyph">•</span>Malnutrition</p><p class="bulletIndent2"><span class="glyph">•</span>Hemoglobinopathies</p><p class="bulletIndent2"><span class="glyph">•</span>Hemolysis (see  <a class="medical medical_review" href="/d/html/5932.html" rel="external">"Overview of hemolytic anemias in children"</a>)</p><p class="bulletIndent2"><span class="glyph">•</span>Rare causes, including carnitine and copper deficiencies</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Dose adjustment</strong> – For children who develop acquired ESA hyporesponsiveness, avoid repeated escalations in ESA dose beyond double the dose at which the Hb had been stable because of concern for direct toxicity related to the elevated ESA dosages [<a href="#rid35">35</a>]. A dose of ESA &gt;6000 international units/<sup>m2</sup> per week in children on peritoneal dialysis was associated with an increased mortality risk [<a href="#rid36">36</a>], although it is uncertain if the excess mortality risk was due to the ESA or rather to a comorbid condition associated with ESA resistance.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Adverse effects</strong> – The adverse effects of ESAs is covered in detail elsewhere (see  <a class="medical medical_review" href="/d/html/1926.html" rel="external">"Treatment of anemia in patients on dialysis", section on 'Adverse effects of ESAs'</a>)," although it should be noted that the data remains scarce and of very low quality in children.</p><p></p><p class="headingAnchor" id="H3987330161"><span class="h1">RISK FOR CARDIOVASCULAR DISEASE</span><span class="headingEndMark"> — </span>Children with CKD are at risk for cardiovascular disease (CVD) [<a href="#rid46">46</a>]. CVD is the leading cause of death in children and young adults with CKD. Cardiac arrest is the most common cause, followed by arrhythmia, cardiomyopathy, and cerebrovascular disease; myocardial infarction is rarely reported in this population. Young adults (25 to 34 years) with CKD have at least a 100-fold higher risk for CVD-related mortality compared with the general population [<a href="#rid47">47</a>]. As a result, CKD in children is one of the chronic diseases associated with an increased risk for accelerated atherosclerosis and early CVD  (<a class="graphic graphic_algorithm graphicRef54963" href="/d/graphic/54963.html" rel="external">algorithm 2</a>). (See  <a class="medical medical_review" href="/d/html/5781.html" rel="external">"Overview of risk factors for development of atherosclerosis and early cardiovascular disease in childhood", section on 'Chronic kidney disease'</a>.)</p><p>The increased incidence of premature CVD is due to the high prevalence of the following CVD risk factors in children with CKD [<a href="#rid48">48</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>Hypertension</p><p class="bulletIndent1"><span class="glyph">●</span>Left ventricular hypertrophy (LVH)</p><p class="bulletIndent1"><span class="glyph">●</span>Obesity [<a href="#rid49">49</a>]</p><p class="bulletIndent1"><span class="glyph">●</span>Dyslipidemia</p><p class="bulletIndent1"><span class="glyph">●</span>Abnormal glucose metabolism</p><p class="bulletIndent1"><span class="glyph">●</span>Metabolic bone disease (see  <a class="medical medical_review" href="/d/html/6092.html" rel="external">"Pediatric chronic kidney disease-mineral and bone disorder (CKD-MBD)", section on 'Complications'</a>)</p><p></p><p class="headingAnchor" id="H4280729683"><span class="h2">Hypertension</span><span class="headingEndMark"> — </span>Strict blood pressure (BP) control that adheres to targeted BP goals  (<a class="graphic graphic_table graphicRef129760" href="/d/graphic/129760.html" rel="external">table 4</a>) is one of the most important modifiable risk factors proven to be effective in slowing the progression of CKD in children [<a href="#rid50">50</a>]. (See  <a class="medical medical_review" href="/d/html/6085.html" rel="external">"Chronic kidney disease in children: Overview of management", section on 'Blood pressure and targeted goals'</a> and  <a class="medical medical_review" href="/d/html/6085.html" rel="external">"Chronic kidney disease in children: Overview of management", section on 'Slow progression of chronic kidney disease'</a>.)</p><p>Hypertension, defined as BP greater than the BP targeted goal on three separate occasions, is common in children with CKD, ranging from 54 to 70 percent of patients [<a href="#rid51">51-55</a>]. Unlike many of the complications of CKD, hypertension can be present in the earliest stages of CKD, although its prevalence increases with progressive declines in glomerular filtration rate (GFR)  (<a class="graphic graphic_table graphicRef89808" href="/d/graphic/89808.html" rel="external">table 1</a>) [<a href="#rid3">3</a>]. Hypertension is usually due to volume expansion and/or activation of the renin-angiotensin-aldosterone system (eg, glomerular disease). In some cases, hypertension may be due, in part, to concurrent medications (eg, corticosteroids or calcineurin inhibitors [eg, <a class="drug drug_pediatric" data-topicid="13193" href="/d/drug information/13193.html" rel="external">cyclosporine</a> or <a class="drug drug_pediatric" data-topicid="12822" href="/d/drug information/12822.html" rel="external">tacrolimus</a>]) that are used to treat the underlying kidney disease.</p><p>Guidelines from the American Academy of Pediatrics and American Heart Association call for an expanded role of the use of ambulatory BP monitoring (ABPM), particularly in the setting of high-risk conditions like CKD [<a href="#rid56">56,57</a>]. It is recommended that children with CKD and hypertension should have at least yearly ABPM when available, both to screen for masked hypertension and to monitor treatment efficacy [<a href="#rid56">56</a>]. A 2012 study of children enrolled in the Chronic Kidney Disease in Children study found a strikingly high proportion (35 percent) of children with CKD who exhibited masked hypertension (eg, normal clinic BP but abnormal 24-hour ABPM) [<a href="#rid58">58</a>]. Target-organ changes such as LVH appear to be more closely correlated with ABPM-based readings than office-based readings [<a href="#rid52">52</a>]. Participants with the highest mean arterial pressures on sleep and wake ABPM studies demonstrate an increased risk of CKD progression over time [<a href="#rid59">59,60</a>], identifying uncontrolled hypertension as an important modifiable risk factor for CKD progression.</p><p>Treatment of hypertension includes both pharmacologic and nonpharmacologic therapy:</p><p class="headingAnchor" id="H532149159"><span class="h3">Nonpharmacologic therapy</span><span class="headingEndMark"> — </span>For all children with CKD and hypertension, nonpharmacologic treatment should be initiated with lifestyle changes, including weight reduction for children who are overweight, regular aerobic exercise regimen, dietary measures (eg, diet rich in fruit/vegetables and reduced fat and salt), stress reduction, and avoidance of excess alcohol consumption, caffeine, energy drinks, and smoke or vaping exposure. (See  <a class="medical medical_review" href="/d/html/6131.html" rel="external">"Nonemergent treatment of hypertension in children and adolescents", section on 'Nonpharmacologic therapy'</a>.)</p><p class="headingAnchor" id="H2298791656"><span class="h3">Pharmacologic therapy</span><span class="headingEndMark"> — </span>Pharmacologic therapy is indicated in children with CKD at the time hypertension is diagnosed. Although lifestyle factors are important adjunctive treatment strategies, the treatment of hypertension in children with CKD differs from children without CKD in whom a three- to six-month trial of lifestyle modifications may be an appropriate initial treatment strategy.</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Target BP goals</strong> – We use the following target BP goals for office measurements  (<a class="graphic graphic_table graphicRef129760" href="/d/graphic/129760.html" rel="external">table 4</a>). These targets represent the thresholds for normal BP for pediatric patients with CKD, as defined by the 2017 American Academy of Pediatrics and American Heart Association guidelines [<a href="#rid56">56</a>]:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>For children with CKD (&lt;13 years of age), target systolic and diastolic BPs are &lt;90<sup>th</sup> percentile of normative data for age, gender, and height  (<a class="graphic graphic_table graphicRef63856" href="/d/graphic/63856.html" rel="external">table 5</a> and <a class="graphic graphic_table graphicRef52646" href="/d/graphic/52646.html" rel="external">table 6</a> and <a class="graphic graphic_figure graphicRef62005" href="/d/graphic/62005.html" rel="external">figure 2</a>)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>For adolescents with CKD (≥13 years of age), target BP is ≤120/80 mmHg</p><p></p><p>We also use ABPM annually to target strict BP control with a target goal of a 24-hour mean arterial BP below the 50<sup>th</sup> percentile based on pediatric ABPM normative data for gender and height, as recommended by the 2017 American Academy of Pediatrics guidelines  (<a class="graphic graphic_table graphicRef94618" href="/d/graphic/94618.html" rel="external">table 7</a> and <a class="graphic graphic_table graphicRef94616" href="/d/graphic/94616.html" rel="external">table 8</a> and <a class="graphic graphic_table graphicRef94619" href="/d/graphic/94619.html" rel="external">table 9</a> and <a class="graphic graphic_table graphicRef94617" href="/d/graphic/94617.html" rel="external">table 10</a>) [<a href="#rid56">56</a>].</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Choice of drugs</strong></p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Renin-angiotensin-aldosterone system inhibitors</strong> – When pharmacologic therapy is initiated, the preferred choice of an antihypertensive agent is one that targets the renin-angiotensin system (angiotensin-converting enzyme [ACE] inhibitor or angiotensin II receptor blockers [ARBs]) as it provides the added benefit of reducing proteinuria [<a href="#rid1">1,50,61-66</a>]. ACE inhibitors or ARBs appear to be more beneficial in slowing the progression of CKD compared with other agents in patients with CKD [<a href="#rid66">66</a>]. (See  <a class="medical medical_review" href="/d/html/6085.html" rel="external">"Chronic kidney disease in children: Overview of management", section on 'Slow progression of chronic kidney disease'</a> and  <a class="medical medical_review" href="/d/html/3872.html" rel="external">"Overview of hypertension in acute and chronic kidney disease", section on 'Choice of antihypertensive therapy'</a>.)</p><p></p><p class="bulletIndent2">In our practice, we prefer to initiate therapy with an ACE inhibitor as there are more data on the safety and efficacy of this class of drugs in children compared with ARBs. We start with an initial dose of <a class="drug drug_pediatric" data-topicid="83360" href="/d/drug information/83360.html" rel="external">enalapril</a> of 0.08 mg/kg per day (maximum of 5 mg/day), which is titrated to a maximum dose of 0.6 mg/kg per day (maximum of 40 mg/day) based on the response of the patient's BP and results of lab tests (eg, serum potassium). We use enalapril because its long half-life allows once a day dosing. Alternative long-acting ACE inhibitors commonly used in children are <a class="drug drug_pediatric" data-topicid="12558" href="/d/drug information/12558.html" rel="external">lisinopril</a> and <a class="drug drug_general" data-topicid="9851" href="/d/drug information/9851.html" rel="external">ramipril</a>, which are also administered once a day. (See  <a class="medical medical_review" href="/d/html/6131.html" rel="external">"Nonemergent treatment of hypertension in children and adolescents", section on 'ACE inhibitors'</a>.)</p><p></p><p class="bulletIndent2">In patients who develop a cough with an ACE inhibitor, we use the ARB drug <a class="drug drug_pediatric" data-topicid="13047" href="/d/drug information/13047.html" rel="external">losartan</a> at an initial dose of 0.7 mg/kg per day (maximum of 50 mg/day), which is titrated to a maximum dose of 1.4 mg/kg per day (maximum of 100 mg/day). ARBs may induce a more complete inhibition of the renin-angiotensin-aldosterone system but do not affect bradykinin and thereby have a lower risk of cough and angioedema than ACE inhibitors. We typically avoid combination therapy of ACE inhibitors and ARBs as data from adults suggest an increased likelihood of adverse events. (See  <a class="medical medical_review" href="/d/html/3816.html" rel="external">"Major side effects of angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers", section on 'Combination of ACE inhibitors and ARBs'</a>.)</p><p></p><p class="bulletIndent2">Both ACE inhibitors and ARBs should be used cautiously if the GFR is less than 60 mL/min per 1.73 m² [<a href="#rid64">64,66</a>]. Of note, discontinuation of ACE inhibitor/ARB in children with advanced CKD has been associated with more rapid CKD progression [<a href="#rid66">66</a>]. Since the decline in GFR induced by an ACE inhibitor/ARB typically occurs within the first few days after the onset of therapy, the serum creatinine and potassium concentrations should be remeasured within 7 to 10 days after the institution of therapy or dose titration to ensure that the therapy has not adversely affected the GFR, resulting in a significant elevation of serum creatinine and/or hyperkalemia.</p><p></p><p class="bulletIndent2">The teratogenic potential of these drugs in women of childbearing age also should be discussed with any pubertal adolescent female when administration of either an ACE inhibitor or ARB is being considered. (See  <a class="medical medical_review" href="/d/html/3816.html" rel="external">"Major side effects of angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers"</a> and  <a class="medical medical_review" href="/d/html/4789.html" rel="external">"Adverse effects of angiotensin converting enzyme inhibitors and receptor blockers in pregnancy"</a>.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Diuretics</strong> – A diuretic may be used for patients with hypertension and edema. For patients in early stages of CKD (estimated GFR [eGFR] ≥45 mL/min per 1.73 m<sup>2</sup>), a thiazide diuretic such as <a class="drug drug_pediatric" data-topicid="13357" href="/d/drug information/13357.html" rel="external">hydrochlorothiazide</a> (1 to 3 mg/kg per day to a maximum of 50 mg/day) is often effective. For patients with more advanced CKD, a loop diuretic is recommended, because thiazides become less effective as monotherapy as the GFR declines. In our practice, we use the loop diuretic <a class="drug drug_pediatric" data-topicid="13329" href="/d/drug information/13329.html" rel="external">furosemide</a> at a dose of 0.5 to 2 mg/kg per day in one to two divided doses.</p><p></p><p class="headingAnchor" id="H4202499252"><span class="h2">Left ventricular hypertrophy</span><span class="headingEndMark"> — </span>LVH is a common finding in patients with CKD and occurs as a response to mechanical or hemodynamic overload [<a href="#rid46">46</a>]. There are two different patterns of LVH: concentric LVH, which occurs in the presence of hypertension, and eccentric LVH, which is associated with volume overload and anemia [<a href="#rid67">67</a>]. Preventive measures to reduce the risk of LVH include strict BP control, maintenance of a healthy body weight, and avoidance of volume overload and anemia. (See <a class="local">'Hypertension'</a> above and <a class="local">'Sodium and water homeostasis'</a> above and <a class="local">'Anemia'</a> above.)</p><p>In a study of 366 children with CKD stage G2 through G4, 17 percent of the cohort had LVH detected by echocardiography [<a href="#rid52">52</a>]. LVH was more common in children with confirmed and masked hypertension compared with those with normal BP measurements (34, 20, and 8 percent, respectively). A subsequent analysis of 725 children enrolled in the Chronic Kidney Disease in Children study found that adiposity was independently associated with markers of cardiac damage, LV mass index, Z-score, and LVH, particularly in girls, suggesting that obesity is a potentially modifiable risk factor for CVD [<a href="#rid68">68</a>].</p><p class="headingAnchor" id="H3458822160"><span class="h2">Dyslipidemia</span><span class="headingEndMark"> — </span>Abnormal lipid metabolism is common in patients with CKD and is one of the primary factors that increase the risk for CVD [<a href="#rid69">69</a>]. Children greater than two years of age with CKD (a known associated atherosclerotic condition) should be screened for dyslipidemia annually  (<a class="graphic graphic_algorithm graphicRef54963" href="/d/graphic/54963.html" rel="external">algorithm 2</a>), consistent with guidelines from the American Academy of Pediatrics, American Heart Association, Kidney Disease: Improving Global Outcomes (KDIGO), and an expert panel sponsored by the United States National Heart, Lung, and Blood Institute [<a href="#rid70">70</a>]. (See  <a class="medical medical_society_guidelines" href="/d/html/110734.html" rel="external">"Society guideline links: Lipid disorders and atherosclerosis in children"</a>.)</p><p>Observational data in children have shown that the risk of dyslipidemia (eg, abnormally high triglyceride and non-high-density lipid cholesterol [non-HDL-C] levels and decreasing HDL-C level) is high in children with CKD and increases as the GFR declines, with the highest risk for those with end-stage kidney disease and following kidney transplantation  (<a class="graphic graphic_algorithm graphicRef54963" href="/d/graphic/54963.html" rel="external">algorithm 2</a>) [<a href="#rid48">48,70-77</a>].</p><p class="headingAnchor" id="H825551075"><span class="h3">Our approach</span><span class="headingEndMark"> — </span>In our practice, children greater than two years of age with CKD (including dialysis patients and those with kidney transplant) are evaluated with a fasting lipid profile  (<a class="graphic graphic_algorithm graphicRef54963" href="/d/graphic/54963.html" rel="external">algorithm 2</a>) [<a href="#rid15">15,70,78</a>]. If a lipid abnormality is detected, management consists of therapeutic lifestyle changes with dietary recommendations  (<a class="graphic graphic_table graphicRef78256" href="/d/graphic/78256.html" rel="external">table 11</a>) based on the severity of CKD and made in concert with our pediatric renal dietitian. We consider the use of statins only in older children in whom the magnitude of dyslipidemia remains severe (eg, low-density lipoprotein cholesterol [LDL] &gt;130 mg/dL) despite dietary management. (See  <a class="medical medical_society_guidelines" href="/d/html/110734.html" rel="external">"Society guideline links: Lipid disorders and atherosclerosis in children"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>In children with CKD stage G5 (end-stage kidney disease), a very restrictive diet is prescribed  (<a class="graphic graphic_table graphicRef82404" href="/d/graphic/82404.html" rel="external">table 12</a>) [<a href="#rid15">15</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>In children with CKD with hypertriglyceridemia (fasting level &gt;500 mg/dL [&gt;5.65 mmol/L]), a very low-fat diet (fat content less than 15 percent of the total caloric intake) with substitution of medium-chain triglycerides and fish oil instead of long-chain triglycerides is prescribed [<a href="#rid78">78</a>]. However, in children who are malnourished, dietary changes should be made judiciously, if at all.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Statin therapy may be considered only in older patients (males ≥10 years of age and postmenarchal female patients) with severely elevated LDL-C levels despite nonpharmacologic therapy. The decision is made jointly with the family and patient (if appropriate) after considering the currently available evidence and the potential for adverse effects of statin therapy. (See  <a class="medical medical_review" href="/d/html/17048.html" rel="external">"Dyslipidemia in children and adolescents: Management", section on 'Statin therapy'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Fibric acid derivatives or <a class="drug drug_pediatric" data-topicid="12642" href="/d/drug information/12642.html" rel="external">niacin</a> should <strong>not</strong> be used as there is a paucity of evidence regarding their safety and efficacy [<a href="#rid78">78</a>].</p><p></p><p>The screening and management of pediatric dyslipidemia are discussed in greater detail separately. (See  <a class="medical medical_review" href="/d/html/16972.html" rel="external">"Dyslipidemia in children and adolescents: Definition, screening, and diagnosis"</a> and  <a class="medical medical_review" href="/d/html/17048.html" rel="external">"Dyslipidemia in children and adolescents: Management"</a>.)</p><p class="headingAnchor" id="H4093636865"><span class="h1">MALNUTRITION AND POOR GROWTH</span><span class="headingEndMark"> — </span>Children with CKD require special considerations with regards to dietary requirements [<a href="#rid11">11</a>]. Although caloric and energy needs are similar to age-appropriate healthy children, children with CKD who have growth faltering often require 100 to 120 percent of Daily Recommended Intake for calories to achieve optimal growth. Additionally, protein restriction is not typically advised, with recommendations of 100 to 140 percent of Daily Recommended Intake for protein for CKD and 100 to 120 percent for end-stage kidney disease patients [<a href="#rid11">11</a>]. Careful management of the nutritional status of children with CKD, ideally under the supervision of a dietician, is recommended to provide adequate energy, protein, and electrolytes to optimize growth. Supplemental tube feedings through a gastrostomy or nasogastric tube are often required in infants and young children with more advanced kidney disease.</p><p>Growth failure is frequently a hallmark of pediatric CKD. The etiology of growth failure is multifactorial (metabolic acidosis, decreased caloric intake, CKD-mineral and bone disorder [CKD-MBD], sodium depletion, and alterations in the function of the growth hormone [GH] and insulin-like growth factor axis), and early preventive measures are undertaken to avoid these contributing factors. Growth failure is typically most profound in younger children with moderate to severe CKD. Recombinant human GH (rhGH) therapy may be appropriate for children with impaired linear growth and adequate energy consumption and can have a beneficial effect on the height velocity of children with CKD who are growing poorly [<a href="#rid79">79</a>].</p><p>The prevention and management of growth failure, including the use of rhGH, are discussed in greater detail separately. (See  <a class="medical medical_review" href="/d/html/83284.html" rel="external">"Growth failure in children with chronic kidney disease: Prevention and management"</a> and  <a class="medical medical_review" href="/d/html/6140.html" rel="external">"Growth failure in children with chronic kidney disease: Treatment with growth hormone"</a> and  <a class="medical medical_review" href="/d/html/14555.html" rel="external">"Growth failure in children with chronic kidney disease: Risk factors, evaluation, and diagnosis"</a>.)</p><p class="headingAnchor" id="H2476784442"><span class="h1">ENDOCRINE DYSFUNCTION</span><span class="headingEndMark"> — </span>In patients with CKD, the following endocrine systems become dysfunctional as kidney function progressively deteriorates. Each of these is discussed in greater detail separately.</p><p class="bulletIndent1"><span class="glyph">●</span>Growth hormone (GH) function – CKD is associated with a variety of abnormalities in GH homeostasis including changes in the plasma concentration of GH, its release, and its end-organ responsiveness. In particular, end-organ resistance to GH due to increased levels of insulin growth factor binding proteins appears to play a major role in growth impairment in children with CKD [<a href="#rid80">80</a>]. (See  <a class="medical medical_review" href="/d/html/14555.html" rel="external">"Growth failure in children with chronic kidney disease: Risk factors, evaluation, and diagnosis", section on 'Pathogenesis: Disturbance of growth hormone/IGF-1 axis'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Thyroid function – In patients with CKD, alterations in the production, distribution, and excretion of thyroid hormones occur with increasing kidney dysfunction. These abnormalities are generally characterized by low total and free T4 and T3, a normal thyroid-stimulating hormone level, and normal or decreased thyroid hormone-binding globulin levels or thyrotropin-releasing hormone stimulation test results. These findings are consistent with the "sick euthyroid syndrome" seen in other chronic diseases. (See  <a class="medical medical_review" href="/d/html/1977.html" rel="external">"Thyroid function in chronic kidney disease"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Gonadal hormone function – There are abnormalities in gonadal hormones in both male and female patients, which result in delayed puberty in two-thirds of adolescents with end-stage kidney disease [<a href="#rid81">81</a>]. Although the onset of puberty is frequently delayed, progression through the pubertal stages appears to be normal or only slightly delayed [<a href="#rid6">6</a>].</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>In males, abnormalities include reduced levels of serum free testosterone, dihydrotestosterone, and adrenal androgens and increases in serum luteinizing hormone (LH) and follicle-stimulating hormone (FSH). (See  <a class="medical medical_review" href="/d/html/7459.html" rel="external">"Causes of primary hypogonadism in males", section on 'Chronic kidney disease'</a>.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Postpubertal females with CKD have reduced serum estrogen, elevated LH and FSH, and loss of the LH pulsatile pattern. These disturbances result in anovulation. In a study of 287 females with CKD, the median age at menarche was similar between females with CKD and healthy normal females [<a href="#rid82">82</a>]. However, 10 percent of this cohort had delayed menarche, which appeared to be associated with short stature.</p><p></p><p class="headingAnchor" id="H1853214803"><span class="h1">NEURODEVELOPMENTAL IMPAIRMENT</span><span class="headingEndMark"> — </span>CKD is associated with neurological comorbidities ranging from seizures and severe intellectual disability to more subtle deficits resulting in poor school performance [<a href="#rid83">83,84</a>]. Children with CKD have lower scores for executive function, memory (verbal and visual), mathematics, reading, and spelling compared with the general population [<a href="#rid85">85</a>]. In addition, poor academic performance may be related to school absenteeism, a common problem for children with CKD [<a href="#rid84">84,86</a>]. Other reported factors associated with cognitive impairment in children with CKD include high blood lead level [<a href="#rid87">87</a>] and changes in regional cerebral blood flow [<a href="#rid88">88</a>]. In addition, daytime sleepiness and fatigue are commonly seen in children with CKD and may impact their school performance [<a href="#rid89">89,90</a>].</p><p>Children on dialysis have lower scores on cognitive testing than those with milder CKD [<a href="#rid91">91,92</a>]. This association may be explained in part by effects of uremia on cognition and neurodevelopment. Children with mild CKD may display normal cognitive function on intellectual testing; however, these children remain at risk for neurocognitive dysfunction and may have poorer scores on testing for adaptive behavior and attention [<a href="#rid91">91,93</a>].</p><p>Because of the risk of neurodevelopmental impairment, early developmental surveillance and screening are important components of routine health care for children with CKD to identify children with or at-risk for neurodevelopmental delay. (See  <a class="medical medical_review" href="/d/html/6085.html" rel="external">"Chronic kidney disease in children: Overview of management", section on 'Neurodevelopment assessment'</a>.)</p><p class="headingAnchor" id="H849840352"><span class="h1">UREMIA</span><span class="headingEndMark"> — </span>With CKD progression, a constellation of signs and symptoms referred to as uremia develops. Manifestations, which can be observed even in children with mild to moderate CKD and increase in prevalence with decreasing kidney function, include fatigue; anorexia; nausea; vomiting; growth retardation; pruritus; peripheral neuropathy; and central nervous system abnormalities ranging from loss of concentration and lethargy to seizures, coma, and death [<a href="#rid4">4</a>].</p><p>Other complications of uremia include the following:</p><p class="bulletIndent1"><span class="glyph">●</span>Platelet dysfunction – Patients who are uremic also have an increased tendency to bleed secondary to abnormal platelet adhesion and aggregation properties</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Pericardial disease – Pericardial disease (pericarditis and pericardial effusion) is an indication to institute dialysis in children with CKD</p><p></p><p class="headingAnchor" id="H3977234161"><span class="h2">Uremic bleeding</span><span class="headingEndMark"> — </span>An increased tendency for bleeding is present in patients with severe CKD due primarily to abnormalities in platelet adhesion and aggregation properties. In asymptomatic patients, no specific therapy is required. However, in patients who are actively bleeding or who are about to undergo a surgical or invasive procedure (such as kidney biopsy), the platelet abnormality should be addressed by consideration of the following preventative treatment options. (See  <a class="medical medical_review" href="/d/html/1947.html" rel="external">"Uremic platelet dysfunction"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_pediatric" data-topicid="13212" href="/d/drug information/13212.html" rel="external">Desmopressin</a> (dDAVP), an analog of antidiuretic hormone that is the simplest and least toxic acute treatment – In our practice, dDAVP is often given to children with uremia prior to invasive procedures deemed high risk for bleeding. It is administered intravenously or subcutaneously at a dose of 0.3 mcg/kg with an onset of effect within one hour of administration; the effect lasts for six to eight hours.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Cryoprecipitate (1 to 2 units/10 kg) – The effect lasts for 24 to 36 hours, but there is an increased risk of transmitted infectious diseases. Therefore, this is not considered routinely for prophylaxis but reserved for use in the setting of active bleeding.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Estrogen (0.6 mg/kg per day for five days) – The onset of effect is over 6 to 24 hours, but the effect lasts for two to three weeks.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Correction of anemia – An improved hemoglobin (Hb; hematocrit) is believed to facilitate increased interaction between platelets and blood vessels.</p><p></p><p class="headingAnchor" id="H1735742710"><span class="h2">Uremic pericarditis</span><span class="headingEndMark"> — </span>Uremic pericardial disease (pericarditis and pericardial effusion) is seen only in the late stages of CKD and is an indication to institute dialysis. Most patients with uremic pericarditis respond rapidly to dialysis, with resolution of chest pain as well as a decrease in the size of the pericardial effusion.</p><p class="headingAnchor" id="H692885840"><span class="h1">SOCIETY GUIDELINE LINKS</span><span class="headingEndMark"> — </span>Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See  <a class="medical medical_society_guidelines" href="/d/html/112930.html" rel="external">"Society guideline links: Chronic kidney disease-mineral and bone disorder"</a>.)</p><p class="headingAnchor" id="H1595441274"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Definition</strong> – Chronic kidney disease (CKD) refers to a state of irreversible kidney damage and/or reduction of kidney function that is associated with a wide range of complications. Complications begin to be observed with moderate to severe loss of loss of glomerular filtration rate (GFR; ie, GFR &lt;45 mL/min per 1.73 m<sup>2</sup>)  (<a class="graphic graphic_table graphicRef89808" href="/d/graphic/89808.html" rel="external">table 1</a>). (See <a class="local">'Definitions'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Fluid and electrolyte abnormalities:</strong></p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Salt wasting and hypovolemia</strong> – Salt wasting and poor urinary concentrating ability are often seen in children with obstructive uropathy and/or dysplastic kidneys. These children are at risk for clinically significant hypovolemia as they are unable to respond appropriately to acute intravascular volume depletion that can occur with episodes of vomiting and diarrhea. (See <a class="local">'Sodium and water homeostasis'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Salt and fluid overload</strong> – As kidney function becomes severely compromised (GFR &lt;15 mL/min per 1.73 m<sup>2</sup>), sodium and water retention may result in chronic intravascular volume overload. In children with CKD and volume overload, we suggest a combination trial of dietary sodium restriction and diuretic therapy (<a class="grade" href="https://medilib.ir/uptodate/show/grade_6" rel="external">Grade 2C</a>). In our practice, we limit the sodium intake to 1.5 to 2.4 g/day. Thiazide diuretics (eg, <a class="drug drug_pediatric" data-topicid="13357" href="/d/drug information/13357.html" rel="external">hydrochlorothiazide</a>) are preferred in the early stages of CKD, while <a class="drug drug_pediatric" data-topicid="13329" href="/d/drug information/13329.html" rel="external">furosemide</a> or another loop diuretic is used in more advanced stages of CKD. (See <a class="local">'Sodium and water homeostasis'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Hyperkalemia</strong> – In children with moderate to severe CKD, we recommend a low-potassium diet to prevent hyperkalemia (<a class="grade" href="https://medilib.ir/uptodate/show/grade_3" rel="external">Grade 1C</a>). Other interventions include the use of loop diuretics (eg, <a class="drug drug_pediatric" data-topicid="13329" href="/d/drug information/13329.html" rel="external">furosemide</a>) and correction of metabolic acidosis. (See <a class="local">'Hyperkalemia'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Metabolic acidosis</strong> – In children with CKD and metabolic acidosis, we suggest administering enteral <a class="drug drug_pediatric" data-topicid="12795" href="/d/drug information/12795.html" rel="external">sodium bicarbonate</a> to maintain a serum bicarbonate level ≥22 mEq/L (<a class="grade" href="https://medilib.ir/uptodate/show/grade_6" rel="external">Grade 2C</a>). Citrate preparations should be avoided as these preparations enhance aluminum absorption. (See <a class="local">'Metabolic acidosis'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>CKD-mineral and bone disorder (CKD-MBD)</strong> – Management of CKD-MBD includes ongoing monitoring of bone metabolism (measurements of serum concentrations of calcium, phosphorus, parathyroid hormone, and alkaline phosphatase levels) and appropriate therapeutic interventions including dietary phosphate restriction, phosphate binders, vitamin D replacement therapy, active vitamin D analogs, and calcimimetic drugs. (See  <a class="medical medical_review" href="/d/html/6092.html" rel="external">"Pediatric chronic kidney disease-mineral and bone disorder (CKD-MBD)"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Anemia</strong> – In children with CKD, hemoglobin (Hb) testing should be performed at least yearly. Anemia is defined as an Hb below the 2.5<sup>th</sup> percentile of normal adjusted for age and sex  (<a class="graphic graphic_table graphicRef57465" href="/d/graphic/57465.html" rel="external">table 3</a>). After eliminating other causes of anemia  (<a class="graphic graphic_algorithm graphicRef130059" href="/d/graphic/130059.html" rel="external">algorithm 1</a>), treatment of anemia due to CKD includes iron supplementation and, in patients with severe CKD, erythropoietin therapy. We suggest administrating an erythropoiesis-stimulating agent (ESA) when the Hb level is &lt;10 g/dL, provided that there is no evidence of iron deficiency or other cause of anemia (<a class="grade" href="https://medilib.ir/uptodate/show/grade_6" rel="external">Grade 2C</a>). When ESA is used in children with CKD, we suggest maintaining the Hb value between 11 and 12 g/dL (<a class="grade" href="https://medilib.ir/uptodate/show/grade_6" rel="external">Grade 2C</a>). (See <a class="local">'Anemia'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Hypertension</strong> – In children with CKD and hypertension, we suggest that an angiotensin-converting enzyme (ACE) inhibitor or an angiotensin II receptor blocker (ARB) be used rather than other classes of antihypertensive agents to maintain targeted blood pressure (BP) goals  (<a class="graphic graphic_table graphicRef129760" href="/d/graphic/129760.html" rel="external">table 4</a>) (<a class="grade" href="https://medilib.ir/uptodate/show/grade_6" rel="external">Grade 2C</a>). (See <a class="local">'Hypertension'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Dyslipidemia</strong> – In children with CKD, screening for dyslipidemia is performed by obtaining fasting lipid profiles on an annual basis. In patients with CKD and dyslipidemia, we suggest an initial trial of nonpharmacologic therapy that includes diet  (<a class="graphic graphic_table graphicRef82404" href="/d/graphic/82404.html" rel="external">table 12</a> and <a class="graphic graphic_table graphicRef78256" href="/d/graphic/78256.html" rel="external">table 11</a>) and daily exercise (<a class="grade" href="https://medilib.ir/uptodate/show/grade_6" rel="external">Grade 2C</a>). We suggest statin therapy be considered in patients greater than 10 years old with a persistently elevated low-density lipoprotein cholesterol (LDL-C) level despite dietary measures (<a class="grade" href="https://medilib.ir/uptodate/show/grade_6" rel="external">Grade 2C</a>). (See <a class="local">'Dyslipidemia'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Malnutrition and growth failure</strong> – In children with CKD, growth failure is a long-recognized complication and may be multifactorial (eg, metabolic acidosis, decreased caloric intake, CKD-MBD, and dysfunction of the growth hormone [GH] and insulin-like growth factor axis). However, poor growth may persist despite measures focused on modifying causal factors. Careful management of the nutritional status of children with CKD, ideally under the supervision of a dietician, is recommended to provide adequate energy, protein, and electrolytes to optimize growth. For these patients with persistent growth impairment, recombinant human GH (rhGH) is an option to improve linear growth. (See  <a class="medical medical_review" href="/d/html/6140.html" rel="external">"Growth failure in children with chronic kidney disease: Treatment with growth hormone"</a> and <a class="local">'Malnutrition and poor growth'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Neurodevelopmental impairment</strong> – Children with CKD are at risk for neurocognitive dysfunction, particularly in executive functioning and attention. Ongoing and early neurodevelopmental assessment is necessary to determine whether early intervention or educational support is needed. (See <a class="local">'Neurodevelopmental impairment'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Uremia</strong> – With progression of CKD, a constellation of signs and symptoms referred to as uremia develops with manifestations of anorexia, nausea, vomiting, growth retardation, peripheral neuropathy, central nervous system abnormalities, increased tendency for bleeding due to platelet dysfunction (uremic bleeding), and pericarditis. In affected children, uremic pericarditis resolves with the successful initiation of kidney replacement therapy. (See <a class="local">'Uremia'</a> above.)</p><p></p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">KDIGO 2012 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease. Kidney Int Suppl 2013; 3:136.</a></li><li><a class="nounderline abstract_t">Pierce CB, Muñoz A, Ng DK, et al. Age- and sex-dependent clinical equations to estimate glomerular filtration rates in children and young adults with chronic kidney disease. Kidney Int 2021; 99:948.</a></li><li><a class="nounderline abstract_t">Wong H, Mylrea K, Feber J, et al. Prevalence of complications in children with chronic kidney disease according to KDOQI. Kidney Int 2006; 70:585.</a></li><li><a class="nounderline abstract_t">Furth SL, Abraham AG, Jerry-Fluker J, et al. Metabolic abnormalities, cardiovascular disease risk factors, and GFR decline in children with chronic kidney disease. Clin J Am Soc Nephrol 2011; 6:2132.</a></li><li><a class="nounderline abstract_t">KDOQI Work Group. KDOQI Clinical Practice Guideline for Nutrition in Children with CKD: 2008 update. Executive summary. Am J Kidney Dis 2009; 53:S11.</a></li><li><a class="nounderline abstract_t">Haffner D. Strategies for Optimizing Growth in Children With Chronic Kidney Disease. Front Pediatr 2020; 8:399.</a></li><li><a class="nounderline abstract_t">Brouillard AM, Deych E, Canter C, Rich MW. Trends in Sodium Intake in Children and Adolescents in the US and the Impact of US Department of Agriculture Guidelines: NHANES 2003-2016. J Pediatr 2020; 225:117.</a></li><li class="breakAll">Panel of Dietary Intakes for Electrolytes and Water, Standing Committee on the Scientific Evaluation of Dietary Reference Intakes, Food and Nutrition Board, Institute of Medicine. Dietary Reference Intakes for Water, Potassium, Sodium, Chloride, and Sulfate. National Academic Press, Washington, DC 2004. Available at: www.nap.edu/books/0309091691/ (Accessed on January 18, 2006).</li><li><a class="nounderline abstract_t">Kurzinski KL, Xu Y, Ng DK, et al. Hyperkalemia in pediatric chronic kidney disease. Pediatr Nephrol 2023; 38:3083.</a></li><li><a class="nounderline abstract_t">Desloovere A, Renken-Terhaerdt J, Tuokkola J, et al. The dietary management of potassium in children with CKD stages 2-5 and on dialysis-clinical practice recommendations from the Pediatric Renal Nutrition Taskforce. Pediatr Nephrol 2021; 36:1331.</a></li><li><a class="nounderline abstract_t">Shaw V, Polderman N, Renken-Terhaerdt J, et al. Energy and protein requirements for children with CKD stages 2-5 and on dialysis-clinical practice recommendations from the Pediatric Renal Nutrition Taskforce. Pediatr Nephrol 2020; 35:519.</a></li><li><a class="nounderline abstract_t">Keung LG. Renastart Use in an Infant on Peritoneal Dialysis. Adv Perit Dial 2017; 33:79.</a></li><li><a class="nounderline abstract_t">Bunchman TE, Wood EG, Schenck MH, et al. Pretreatment of formula with sodium polystyrene sulfonate to reduce dietary potassium intake. Pediatr Nephrol 1991; 5:29.</a></li><li><a class="nounderline abstract_t">Taylor JM, Oladitan L, Carlson S, Hamilton-Reeves JM. Renal formulas pretreated with medications alters the nutrient profile. Pediatr Nephrol 2015; 30:1815.</a></li><li><a class="nounderline abstract_t">National Kidney Foundation. K/DOQI clinical practice guidelines for nutrition in chronic renal failure: 2008 Update. Am J Kidney Dis 2009; 53:S1.</a></li><li><a class="nounderline abstract_t">Portale AA, Wolf M, Jüppner H, et al. Disordered FGF23 and mineral metabolism in children with CKD. Clin J Am Soc Nephrol 2014; 9:344.</a></li><li><a class="nounderline abstract_t">Seeherunvong W, Abitbol CL, Chandar J, et al. Vitamin D insufficiency and deficiency in children with early chronic kidney disease. J Pediatr 2009; 154:906.</a></li><li><a class="nounderline abstract_t">van Husen M, Fischer AK, Lehnhardt A, et al. Fibroblast growth factor 23 and bone metabolism in children with chronic kidney disease. Kidney Int 2010; 78:200.</a></li><li><a class="nounderline abstract_t">Gerson A, Hwang W, Fiorenza J, et al. Anemia and health-related quality of life in adolescents with chronic kidney disease. Am J Kidney Dis 2004; 44:1017.</a></li><li><a class="nounderline abstract_t">K/DOQI Clinical practice guidelines for Bone metabolism and disease in children with chronic kidney disease. Am J Kidney Dis 2005; 46:S12.</a></li><li><a class="nounderline abstract_t">Barrett IR, Papadimitriou DG. Skeletal disorders in children with renal failure. J Pediatr Orthop 1996; 16:264.</a></li><li><a class="nounderline abstract_t">Salusky IB, Kuizon BG, Jüppner H. Special aspects of renal osteodystrophy in children. Semin Nephrol 2004; 24:69.</a></li><li><a class="nounderline abstract_t">Denburg MR, Kumar J, Jemielita T, et al. Fracture Burden and Risk Factors in Childhood CKD: Results from the CKiD Cohort Study. J Am Soc Nephrol 2016; 27:543.</a></li><li><a class="nounderline abstract_t">Fadrowski JJ, Pierce CB, Cole SR, et al. Hemoglobin decline in children with chronic kidney disease: baseline results from the chronic kidney disease in children prospective cohort study. Clin J Am Soc Nephrol 2008; 3:457.</a></li><li><a class="nounderline abstract_t">Warady BA, Ho M. Morbidity and mortality in children with anemia at initiation of dialysis. Pediatr Nephrol 2003; 18:1055.</a></li><li><a class="nounderline abstract_t">Benz RL, Pressman MR, Hovick ET, Peterson DD. A preliminary study of the effects of correction of anemia with recombinant human erythropoietin therapy on sleep, sleep disorders, and daytime sleepiness in hemodialysis patients (The SLEEPO study). Am J Kidney Dis 1999; 34:1089.</a></li><li><a class="nounderline abstract_t">Kausz AT, Obrador GT, Pereira BJ. Anemia management in patients with chronic renal insufficiency. Am J Kidney Dis 2000; 36:S39.</a></li><li><a class="nounderline abstract_t">Yorgin PD, Belson A, Al-Uzri AY, Alexander SR. The clinical efficacy of higher hematocrit levels in children with chronic renal insufficiency and those undergoing dialysis. Semin Nephrol 2001; 21:451.</a></li><li><a class="nounderline abstract_t">Carlson J, Gerson AC, Matheson MB, et al. A longitudinal analysis of the effect of anemia on health-related quality of life in children with mild-to-moderate chronic kidney disease. Pediatr Nephrol 2020; 35:1659.</a></li><li><a class="nounderline abstract_t">Singh NS, Johnson RJ, Matheson MB, et al. A longitudinal analysis of the effect of anemia on executive functions in children with mild to moderate chronic kidney disease. Pediatr Nephrol 2023; 38:829.</a></li><li><a class="nounderline abstract_t">Akchurin O, Molino AR, Schneider MF, et al. Longitudinal Relationship Between Anemia and Statural Growth Impairment in Children and Adolescents With Nonglomerular CKD: Findings From the Chronic Kidney Disease in Children (CKiD) Study. Am J Kidney Dis 2023; 81:457.</a></li><li><a class="nounderline abstract_t">KDOQI, National Kidney Foundation. KDOQI Clinical Practice Guidelines and Clinical Practice Recommendations for Anemia in Chronic Kidney Disease. Am J Kidney Dis 2006; 47:S11.</a></li><li><a class="nounderline abstract_t">Ratcliffe LE, Thomas W, Glen J, et al. Diagnosis and Management of Iron Deficiency in CKD: A Summary of the NICE Guideline Recommendations and Their Rationale. Am J Kidney Dis 2016; 67:548.</a></li><li><a class="nounderline abstract_t">KDOQI. KDOQI Clinical Practice Guideline and Clinical Practice Recommendations for anemia in chronic kidney disease: 2007 update of hemoglobin target. Am J Kidney Dis 2007; 50:471.</a></li><li><a class="nounderline abstract_t">McMurray JJV, Parfrey PS, Adamson JW, et al. Kidney disease: Improving global outcomes (KDIGO) anemia work group. KDIGO clinical practice guideline for anemia in chronic kidney disease. Kidney Int Suppl 2012; 2:279.</a></li><li><a class="nounderline abstract_t">Borzych-Duzalka D, Bilginer Y, Ha IS, et al. Management of anemia in children receiving chronic peritoneal dialysis. J Am Soc Nephrol 2013; 24:665.</a></li><li><a class="nounderline abstract_t">Rheault MN, Molony JT, Nevins T, et al. Hemoglobin of 12 g/dl and above is not associated with increased cardiovascular morbidity in children on hemodialysis. Kidney Int 2017; 91:177.</a></li><li><a class="nounderline abstract_t">Warady BA, Barcia J, Benador N, et al. De novo weekly and biweekly darbepoetin alfa dosing in pediatric patients with chronic kidney disease. Pediatr Nephrol 2018; 33:125.</a></li><li><a class="nounderline abstract_t">Warady BA, Meyer Reigner S, Tirodkar C, Drozdz D. Subcutaneous C.E.R.A. for the Maintenance Treatment of Anemia in Pediatric Patients With CKD: A Phase 2, Open-Label, Single-Arm, Multicenter Study. Am J Kidney Dis 2023; 81:684.</a></li><li><a class="nounderline abstract_t">Warady BA, Abraham AG, Schwartz GJ, et al. Predictors of Rapid Progression of Glomerular and Nonglomerular Kidney Disease in Children and Adolescents: The Chronic Kidney Disease in Children (CKiD) Cohort. Am J Kidney Dis 2015; 65:878.</a></li><li><a class="nounderline abstract_t">De Palo T, Giordano M, Palumbo F, et al. Clinical experience with darbepoietin alfa (NESP) in children undergoing hemodialysis. Pediatr Nephrol 2004; 19:337.</a></li><li><a class="nounderline abstract_t">Warady BA, Arar MY, Lerner G, et al. Darbepoetin alfa for the treatment of anemia in pediatric patients with chronic kidney disease. Pediatr Nephrol 2006; 21:1144.</a></li><li><a class="nounderline abstract_t">Schaefer F, Hoppe B, Jungraithmayr T, et al. Safety and usage of darbepoetin alfa in children with chronic kidney disease: prospective registry study. Pediatr Nephrol 2016; 31:443.</a></li><li><a class="nounderline abstract_t">Fischbach M, Wühl E, Reigner SCM, et al. Efficacy and Long-Term Safety of C.E.R.A. Maintenance in Pediatric Hemodialysis Patients with Anemia of CKD. Clin J Am Soc Nephrol 2018; 13:81.</a></li><li><a class="nounderline abstract_t">Altemose KE, Kumar J, Portale AA, et al. Vitamin D insufficiency, hemoglobin, and anemia in children with chronic kidney disease. Pediatr Nephrol 2018; 33:2131.</a></li><li><a class="nounderline abstract_t">Mitsnefes MM. Cardiovascular disease in children with chronic kidney disease. J Am Soc Nephrol 2012; 23:578.</a></li><li><a class="nounderline abstract_t">Foley RN, Parfrey PS, Sarnak MJ. Clinical epidemiology of cardiovascular disease in chronic renal disease. Am J Kidney Dis 1998; 32:S112.</a></li><li><a class="nounderline abstract_t">Wilson AC, Schneider MF, Cox C, et al. Prevalence and correlates of multiple cardiovascular risk factors in children with chronic kidney disease. Clin J Am Soc Nephrol 2011; 6:2759.</a></li><li><a class="nounderline abstract_t">Lalan S, Jiang S, Ng DK, et al. Cardiometabolic Risk Factors, Metabolic Syndrome, and Chronic Kidney Disease Progression in Children. J Pediatr 2018; 202:163.</a></li><li><a class="nounderline abstract_t">ESCAPE Trial Group, Wühl E, Trivelli A, et al. Strict blood-pressure control and progression of renal failure in children. N Engl J Med 2009; 361:1639.</a></li><li><a class="nounderline abstract_t">Flynn JT, Mitsnefes M, Pierce C, et al. Blood pressure in children with chronic kidney disease: a report from the Chronic Kidney Disease in Children study. Hypertension 2008; 52:631.</a></li><li><a class="nounderline abstract_t">Mitsnefes M, Flynn J, Cohn S, et al. Masked hypertension associates with left ventricular hypertrophy in children with CKD. J Am Soc Nephrol 2010; 21:137.</a></li><li><a class="nounderline abstract_t">Kogon AJ, Pierce CB, Cox C, et al. Nephrotic-range proteinuria is strongly associated with poor blood pressure control in pediatric chronic kidney disease. Kidney Int 2014; 85:938.</a></li><li><a class="nounderline abstract_t">Halbach SM, Martz K, Mattoo T, Flynn J. Predictors of blood pressure and its control in pediatric patients receiving dialysis. J Pediatr 2012; 160:621.</a></li><li><a class="nounderline abstract_t">Wilson AC, Flynn JT. Blood pressure in children with chronic kidney disease: lessons learned from the Chronic Kidney Disease in Children Cohort Study. Pediatr Nephrol 2020; 35:1203.</a></li><li><a class="nounderline abstract_t">Flynn JT, Kaelber DC, Baker-Smith CM, et al. Clinical Practice Guideline for Screening and Management of High Blood Pressure in Children and Adolescents. Pediatrics 2017; 140.</a></li><li><a class="nounderline abstract_t">Flynn JT, Urbina EM, Brady TM, et al. Ambulatory Blood Pressure Monitoring in Children and Adolescents: 2022 Update: A Scientific Statement From the American Heart Association. Hypertension 2022; 79:e114.</a></li><li><a class="nounderline abstract_t">Samuels J, Ng D, Flynn JT, et al. Ambulatory blood pressure patterns in children with chronic kidney disease. Hypertension 2012; 60:43.</a></li><li><a class="nounderline abstract_t">Dionne JM, Jiang S, Ng DK, et al. Mean Arterial Pressure and Chronic Kidney Disease Progression in the CKiD Cohort. Hypertension 2021; 78:65.</a></li><li><a class="nounderline abstract_t">Guzman-Limon ML, Jiang S, Ng D, et al. Nocturnal Hypertension in Children With Chronic Kidney Disease Is Common and Associated With Progression to Kidney Replacement Therapy. Hypertension 2022; 79:2288.</a></li><li><a class="nounderline abstract_t">van den Belt SM, Heerspink HJL, Gracchi V, et al. Early Proteinuria Lowering by Angiotensin-Converting Enzyme Inhibition Predicts Renal Survival in Children with CKD. J Am Soc Nephrol 2018; 29:2225.</a></li><li><a class="nounderline abstract_t">Kidney Disease Outcomes Quality Initiative (K/DOQI). K/DOQI clinical practice guidelines on hypertension and antihypertensive agents in chronic kidney disease. Am J Kidney Dis 2004; 43:S1.</a></li><li><a class="nounderline abstract_t">White CT, Macpherson CF, Hurley RM, Matsell DG. Antiproteinuric effects of enalapril and losartan: a pilot study. Pediatr Nephrol 2003; 18:1038.</a></li><li><a class="nounderline abstract_t">Soergel M, Verho M, Wühl E, et al. Effect of ramipril on ambulatory blood pressure and albuminuria in renal hypertension. Pediatr Nephrol 2000; 15:113.</a></li><li><a class="nounderline abstract_t">Franscini LM, Von Vigier RO, Pfister R, et al. Effectiveness and safety of the angiotensin II antagonist irbesartan in children with chronic kidney diseases. Am J Hypertens 2002; 15:1057.</a></li><li><a class="nounderline abstract_t">van den Belt SM, Heerspink HJL, Kirchner M, et al. Discontinuation of RAAS Inhibition in Children with Advanced CKD. Clin J Am Soc Nephrol 2020; 15:625.</a></li><li><a class="nounderline abstract_t">Mitsnefes MM. Cardiovascular complications of pediatric chronic kidney disease. Pediatr Nephrol 2008; 23:27.</a></li><li><a class="nounderline abstract_t">Brady TM, Roem J, Cox C, et al. Adiposity, Sex, and Cardiovascular Disease Risk in Children With CKD: A Longitudinal Study of Youth Enrolled in the Chronic Kidney Disease in Children (CKiD) Study. Am J Kidney Dis 2020; 76:166.</a></li><li><a class="nounderline abstract_t">Baek HS, Kim SH, Kang HG, et al. Dyslipidemia in pediatric CKD patients: results from KNOW-PedCKD (KoreaN cohort study for Outcomes in patients With Pediatric CKD). Pediatr Nephrol 2020; 35:1455.</a></li><li><a class="nounderline abstract_t">Kidney Disease: Improving Global Outcomes (KDIGO) Lipid Work Group. KDIGO Clinical Practice Guideline for Lipid Management in Chronic Kidney Disease: Chapter 3: Assessment of lipid status in children with CKD. Kidney Int Suppl 2013; 3:280.</a></li><li><a class="nounderline abstract_t">Saland JM, Kupferman JC, Pierce CB, et al. Change in Dyslipidemia with Declining Glomerular Filtration Rate and Increasing Proteinuria in Children with CKD. Clin J Am Soc Nephrol 2019; 14:1711.</a></li><li><a class="nounderline abstract_t">Saland JM, Pierce CB, Mitsnefes MM, et al. Dyslipidemia in children with chronic kidney disease. Kidney Int 2010; 78:1154.</a></li><li><a class="nounderline abstract_t">Saland JM, Ginsberg H, Fisher EA. Dyslipidemia in pediatric renal disease: epidemiology, pathophysiology, and management. Curr Opin Pediatr 2002; 14:197.</a></li><li><a class="nounderline abstract_t">Saland JM, Ginsberg HN. Lipoprotein metabolism in chronic renal insufficiency. Pediatr Nephrol 2007; 22:1095.</a></li><li><a class="nounderline abstract_t">Bonthuis M, van Stralen KJ, Jager KJ, et al. Dyslipidaemia in children on renal replacement therapy. Nephrol Dial Transplant 2014; 29:594.</a></li><li><a class="nounderline abstract_t">Sethna CB, Ng DK, Jiang S, et al. Cardiovascular disease risk among children with focal segmental glomerulosclerosis: a report from the chronic kidney disease in children study. Pediatr Nephrol 2019; 34:1403.</a></li><li><a class="nounderline abstract_t">Drożdż D, Kwinta P, Sztefko K, et al. Oxidative Stress Biomarkers and Left Ventricular Hypertrophy in Children with Chronic Kidney Disease. Oxid Med Cell Longev 2016; 2016:7520231.</a></li><li><a class="nounderline abstract_t">Kidney Disease: Improving Global Outcomes (KDIGO) Lipid Work Group. KDIGO Clinical Practice Guideline for Lipid Management in Chronic Kidney Disease: Chapter 6: Triglyceride-lowering treatment in children. Kidney Int Suppl 2013; 3:286.</a></li><li><a class="nounderline abstract_t">Drube J, Wan M, Bonthuis M, et al. Clinical practice recommendations for growth hormone treatment in children with chronic kidney disease. Nat Rev Nephrol 2019; 15:577.</a></li><li><a class="nounderline abstract_t">Tönshoff B, Kiepe D, Ciarmatori S. Growth hormone/insulin-like growth factor system in children with chronic renal failure. Pediatr Nephrol 2005; 20:279.</a></li><li><a class="nounderline abstract_t">van der Heijden BJ, van Dijk PC, Verrier-Jones K, et al. Renal replacement therapy in children: data from 12 registries in Europe. Pediatr Nephrol 2004; 19:213.</a></li><li><a class="nounderline abstract_t">Kim HS, Ng DK, Matheson MB, et al. Delayed menarche in girls with chronic kidney disease and the association with short stature. Pediatr Nephrol 2020; 35:1471.</a></li><li><a class="nounderline abstract_t">Lawry KW, Brouhard BH, Cunningham RJ. Cognitive functioning and school performance in children with renal failure. Pediatr Nephrol 1994; 8:326.</a></li><li><a class="nounderline abstract_t">Harshman LA, Johnson RJ, Matheson MB, et al. Academic achievement in children with chronic kidney disease: a report from the CKiD cohort. Pediatr Nephrol 2019; 34:689.</a></li><li><a class="nounderline abstract_t">Chen K, Didsbury M, van Zwieten A, et al. Neurocognitive and Educational Outcomes in Children and Adolescents with CKD: A Systematic Review and Meta-Analysis. Clin J Am Soc Nephrol 2018; 13:387.</a></li><li><a class="nounderline abstract_t">Richardson KL, Weiss NS, Halbach S. Chronic School Absenteeism of Children with Chronic Kidney Disease. J Pediatr 2018; 199:267.</a></li><li><a class="nounderline abstract_t">Ruebner RL, Hooper SR, Parrish C, et al. Environmental lead exposure is associated with neurocognitive dysfunction in children with chronic kidney disease. Pediatr Nephrol 2019; 34:2371.</a></li><li><a class="nounderline abstract_t">Liu HS, Hartung EA, Jawad AF, et al. Regional Cerebral Blood Flow in Children and Young Adults with Chronic Kidney Disease. Radiology 2018; 288:849.</a></li><li><a class="nounderline abstract_t">Roumelioti ME, Wentz A, Schneider MF, et al. Sleep and fatigue symptoms in children and adolescents with CKD: a cross-sectional analysis from the chronic kidney disease in children (CKiD) study. Am J Kidney Dis 2010; 55:269.</a></li><li><a class="nounderline abstract_t">Sinha R, Davis ID, Matsuda-Abedini M. Sleep disturbances in children and adolescents with non-dialysis-dependent chronic kidney disease. Arch Pediatr Adolesc Med 2009; 163:850.</a></li><li><a class="nounderline abstract_t">Hooper SR, Gerson AC, Butler RW, et al. Neurocognitive functioning of children and adolescents with mild-to-moderate chronic kidney disease. Clin J Am Soc Nephrol 2011; 6:1824.</a></li><li><a class="nounderline abstract_t">Mendley SR, Matheson MB, Shinnar S, et al. Duration of chronic kidney disease reduces attention and executive function in pediatric patients. Kidney Int 2015; 87:800.</a></li><li><a class="nounderline abstract_t">Johnson RJ, Gerson AC, Harshman LA, et al. A longitudinal examination of parent-reported emotional-behavioral functioning of children with mild to moderate chronic kidney disease. Pediatr Nephrol 2020; 35:1287.</a></li></ol></div><div id="topicVersionRevision">Topic 128353 Version 14.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : KDIGO 2012 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33301749" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Age- and sex-dependent clinical equations to estimate glomerular filtration rates in children and young adults with chronic kidney disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16788689" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Prevalence of complications in children with chronic kidney disease according to KDOQI.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21841064" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Metabolic abnormalities, cardiovascular disease risk factors, and GFR decline in children with chronic kidney disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19231749" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : KDOQI Clinical Practice Guideline for Nutrition in Children with CKD: 2008 update. Executive summary.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32850527" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Strategies for Optimizing Growth in Children With Chronic Kidney Disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32600669" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Trends in Sodium Intake in Children and Adolescents in the US and the Impact of US Department of Agriculture Guidelines: NHANES 2003-2016.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32600669" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Trends in Sodium Intake in Children and Adolescents in the US and the Impact of US Department of Agriculture Guidelines: NHANES 2003-2016.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/36939915" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Hyperkalemia in pediatric chronic kidney disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33730284" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : The dietary management of potassium in children with CKD stages 2-5 and on dialysis-clinical practice recommendations from the Pediatric Renal Nutrition Taskforce.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31845057" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Energy and protein requirements for children with CKD stages 2-5 and on dialysis-clinical practice recommendations from the Pediatric Renal Nutrition Taskforce.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29668438" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Renastart Use in an Infant on Peritoneal Dialysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2025533" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Pretreatment of formula with sodium polystyrene sulfonate to reduce dietary potassium intake.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25930981" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Renal formulas pretreated with medications alters the nutrient profile.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : K/DOQI clinical practice guidelines for nutrition in chronic renal failure: 2008 Update</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24311704" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Disordered FGF23 and mineral metabolism in children with CKD.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19230902" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Vitamin D insufficiency and deficiency in children with early chronic kidney disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20407479" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Fibroblast growth factor 23 and bone metabolism in children with chronic kidney disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15558522" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Anemia and health-related quality of life in adolescents with chronic kidney disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : K/DOQI Clinical practice guidelines for Bone metabolism and disease in children with chronic kidney disease</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8742298" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Skeletal disorders in children with renal failure.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14730512" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Special aspects of renal osteodystrophy in children.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26139439" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Fracture Burden and Risk Factors in Childhood CKD: Results from the CKiD Cohort Study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18235140" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Hemoglobin decline in children with chronic kidney disease: baseline results from the chronic kidney disease in children prospective cohort study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12883982" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Morbidity and mortality in children with anemia at initiation of dialysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10585319" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : A preliminary study of the effects of correction of anemia with recombinant human erythropoietin therapy on sleep, sleep disorders, and daytime sleepiness in hemodialysis patients (The SLEEPO study).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11118157" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Anemia management in patients with chronic renal insufficiency.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11559886" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : The clinical efficacy of higher hematocrit levels in children with chronic renal insufficiency and those undergoing dialysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32333284" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : A longitudinal analysis of the effect of anemia on health-related quality of life in children with mild-to-moderate chronic kidney disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35861871" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : A longitudinal analysis of the effect of anemia on executive functions in children with mild to moderate chronic kidney disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/36481700" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : Longitudinal Relationship Between Anemia and Statural Growth Impairment in Children and Adolescents With Nonglomerular CKD: Findings From the Chronic Kidney Disease in Children (CKiD) Study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16678659" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : KDOQI Clinical Practice Guidelines and Clinical Practice Recommendations for Anemia in Chronic Kidney Disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26763385" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : Diagnosis and Management of Iron Deficiency in CKD: A Summary of the NICE Guideline Recommendations and Their Rationale.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17720528" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : KDOQI Clinical Practice Guideline and Clinical Practice Recommendations for anemia in chronic kidney disease: 2007 update of hemoglobin target.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : Kidney disease: Improving global outcomes (KDIGO) anemia work group. KDIGO clinical practice guideline for anemia in chronic kidney disease</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23471197" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : Management of anemia in children receiving chronic peritoneal dialysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27865440" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : Hemoglobin of 12 g/dl and above is not associated with increased cardiovascular morbidity in children on hemodialysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28815341" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : De novo weekly and biweekly darbepoetin alfa dosing in pediatric patients with chronic kidney disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/36587890" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : Subcutaneous C.E.R.A. for the Maintenance Treatment of Anemia in Pediatric Patients With CKD: A Phase 2, Open-Label, Single-Arm, Multicenter Study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25799137" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : Predictors of Rapid Progression of Glomerular and Nonglomerular Kidney Disease in Children and Adolescents: The Chronic Kidney Disease in Children (CKiD) Cohort.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14745634" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : Clinical experience with darbepoietin alfa (NESP) in children undergoing hemodialysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16724235" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : Darbepoetin alfa for the treatment of anemia in pediatric patients with chronic kidney disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26482252" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : Safety and usage of darbepoetin alfa in children with chronic kidney disease: prospective registry study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29097481" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : Efficacy and Long-Term Safety of C.E.R.A. Maintenance in Pediatric Hemodialysis Patients with Anemia of CKD.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30008129" id="rid44" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>45 : Vitamin D insufficiency, hemoglobin, and anemia in children with chronic kidney disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22383696" id="rid45" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>46 : Cardiovascular disease in children with chronic kidney disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9820470" id="rid46" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>47 : Clinical epidemiology of cardiovascular disease in chronic renal disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21980183" id="rid47" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>48 : Prevalence and correlates of multiple cardiovascular risk factors in children with chronic kidney disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30041938" id="rid48" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>49 : Cardiometabolic Risk Factors, Metabolic Syndrome, and Chronic Kidney Disease Progression in Children.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19846849" id="rid49" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>50 : Strict blood-pressure control and progression of renal failure in children.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18725579" id="rid50" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>51 : Blood pressure in children with chronic kidney disease: a report from the Chronic Kidney Disease in Children study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19917781" id="rid51" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>52 : Masked hypertension associates with left ventricular hypertrophy in children with CKD.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24048375" id="rid52" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>53 : Nephrotic-range proteinuria is strongly associated with poor blood pressure control in pediatric chronic kidney disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22056352" id="rid53" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>54 : Predictors of blood pressure and its control in pediatric patients receiving dialysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31396711" id="rid54" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>55 : Blood pressure in children with chronic kidney disease: lessons learned from the Chronic Kidney Disease in Children Cohort Study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28827377" id="rid55" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>56 : Clinical Practice Guideline for Screening and Management of High Blood Pressure in Children and Adolescents.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35603599" id="rid56" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>57 : Ambulatory Blood Pressure Monitoring in Children and Adolescents: 2022 Update: A Scientific Statement From the American Heart Association.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22585950" id="rid57" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>58 : Ambulatory blood pressure patterns in children with chronic kidney disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34058856" id="rid58" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>59 : Mean Arterial Pressure and Chronic Kidney Disease Progression in the CKiD Cohort.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35979846" id="rid59" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>60 : Nocturnal Hypertension in Children With Chronic Kidney Disease Is Common and Associated With Progression to Kidney Replacement Therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29930161" id="rid60" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>61 : Early Proteinuria Lowering by Angiotensin-Converting Enzyme Inhibition Predicts Renal Survival in Children with CKD.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15114537" id="rid61" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>62 : K/DOQI clinical practice guidelines on hypertension and antihypertensive agents in chronic kidney disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12920631" id="rid62" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>63 : Antiproteinuric effects of enalapril and losartan: a pilot study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11095026" id="rid63" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>64 : Effect of ramipril on ambulatory blood pressure and albuminuria in renal hypertension.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12460701" id="rid64" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>65 : Effectiveness and safety of the angiotensin II antagonist irbesartan in children with chronic kidney diseases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32253275" id="rid65" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>66 : Discontinuation of RAAS Inhibition in Children with Advanced CKD.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17120060" id="rid66" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>67 : Cardiovascular complications of pediatric chronic kidney disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32389356" id="rid67" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>68 : Adiposity, Sex, and Cardiovascular Disease Risk in Children With CKD: A Longitudinal Study of Youth Enrolled in the Chronic Kidney Disease in Children (CKiD) Study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32232640" id="rid68" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>69 : Dyslipidemia in pediatric CKD patients: results from KNOW-PedCKD (KoreaN cohort study for Outcomes in patients With Pediatric CKD).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid69" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>70 : KDIGO Clinical Practice Guideline for Lipid Management in Chronic Kidney Disease: Chapter 3: Assessment of lipid status in children with CKD</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31712386" id="rid70" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>71 : Change in Dyslipidemia with Declining Glomerular Filtration Rate and Increasing Proteinuria in Children with CKD.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20736985" id="rid71" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>72 : Dyslipidemia in children with chronic kidney disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11981290" id="rid72" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>73 : Dyslipidemia in pediatric renal disease: epidemiology, pathophysiology, and management.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17390152" id="rid73" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>74 : Lipoprotein metabolism in chronic renal insufficiency.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24170813" id="rid74" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>75 : Dyslipidaemia in children on renal replacement therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30903375" id="rid75" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>76 : Cardiovascular disease risk among children with focal segmental glomerulosclerosis: a report from the chronic kidney disease in children study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26885251" id="rid76" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>77 : Oxidative Stress Biomarkers and Left Ventricular Hypertrophy in Children with Chronic Kidney Disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid77" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>78 : KDIGO Clinical Practice Guideline for Lipid Management in Chronic Kidney Disease: Chapter 6: Triglyceride-lowering treatment in children</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31197263" id="rid78" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>79 : Clinical practice recommendations for growth hormone treatment in children with chronic kidney disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15692833" id="rid79" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>80 : Growth hormone/insulin-like growth factor system in children with chronic renal failure.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14685843" id="rid80" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>81 : Renal replacement therapy in children: data from 12 registries in Europe.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32337637" id="rid81" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>82 : Delayed menarche in girls with chronic kidney disease and the association with short stature.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7917859" id="rid82" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>83 : Cognitive functioning and school performance in children with renal failure.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30448874" id="rid83" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>84 : Academic achievement in children with chronic kidney disease: a report from the CKiD cohort.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29472306" id="rid84" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>85 : Neurocognitive and Educational Outcomes in Children and Adolescents with CKD: A Systematic Review and Meta-Analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29706492" id="rid85" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>86 : Chronic School Absenteeism of Children with Chronic Kidney Disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31327061" id="rid86" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>87 : Environmental lead exposure is associated with neurocognitive dysfunction in children with chronic kidney disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29893643" id="rid87" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>88 : Regional Cerebral Blood Flow in Children and Young Adults with Chronic Kidney Disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20034719" id="rid88" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>89 : Sleep and fatigue symptoms in children and adolescents with CKD: a cross-sectional analysis from the chronic kidney disease in children (CKiD) study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19736340" id="rid89" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>90 : Sleep disturbances in children and adolescents with non-dialysis-dependent chronic kidney disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21737850" id="rid90" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>91 : Neurocognitive functioning of children and adolescents with mild-to-moderate chronic kidney disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25252026" id="rid91" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>92 : Duration of chronic kidney disease reduces attention and executive function in pediatric patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32157444" id="rid92" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>93 : A longitudinal examination of parent-reported emotional-behavioral functioning of children with mild to moderate chronic kidney disease.</p>
</a>
</div>
</div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
